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ABSTRACT
Advances in obstetric and neonatal care during recent years have led to the survival
of increasing numbers of extremely premature and low birth weight infants. These
infants are, of necessity, subjected to a wide range of stressors and painful
interventions during the course of intensive care. Invasive procedures such as
heelstick and venepuncture are common in the care of very sick infants and
responses to acute pain of this kind have been extensively investigated.
Many other procedures and interventions are performed which, although not causing
direct tissue damage, are likely to be perceived as painful or distressing for neonates.
These may be prolonged such as mechanical ventilation or repeated such as
endotracheal suction. Many disease states will induce an inflammatory response
likely to cause pain that may be persistent or chronic; for example, necrotising
enterocolitis or meningitis. There has been only limited investigation of the
physiological and behavioural responses to chronic or sub acute pain in the newborn
population.
Pain assessment is the key to pain management. Self-report of pain is the gold
standard for pain assessment in older age groups, but in the preverbal infant this is
obviously not available. A simple and accurate means of identifying and measuring
pain would enable appropriate initiation of analgesia and evaluation of its effects.
There are no recognised physiological or behavioural indicators that can be used to
ii
assist with the detection and assessment of chronic pain in infants whether or not
they are undergoing neonatal intensive care, but there are situations in the neonatal
intensive care unit in which one could anticipate that infants would experience
chronic pain.
This study investigates mean heart rate, heart rate variability and the cutaneous flexor
withdrawal reflex as potential indicators of chronic or acute pain in preterm infants.
The relationship between mean heart rate, heart rate variability, pain and analgesia is
explored in two different situations:
1. In preterm infants undergoing chronic pain or distress associated with
mechanical ventilation, randomised to receive morphine or placebo. The
groups are compared to assess whether mean heart rate, heart rate variability
or the cutaneous flexor withdrawal reflex threshold are useful in the
assessment of pain or withdrawal of opiate analgesia in the clinical situation.
2. In infants undergoing the acute pain and stress of ophthalmological
examination for screening for retinopathy of prematurity. These infants were
randomised to receive sucrose solution or placebo. These groups are similarly
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Historically, the newborn infant was believed to be incapable of experiencing pain.
More recently, as increasing research has been carried out, it has become clear that
even the preterm neonate is sufficiently developed anatomically, hormonally and
1 '2
neurophysiologically to perceive and respond to painful stimuli ' . Furthermore, there
is a growing body of evidence from both animal and human studies to suggest that
prolonged or repetitive pain during the neonatal period may increase morbidity and
3 7alter behavioural responses both in the short and long term " .
Yet all newborn infants are exposed to potentially painful or distressing events.
Healthy term neonates undergo a number of unavoidable procedures such as
injection of Vitamin K at birth, heel prick for the Guthrie test in the first week of life
and immunisations during the first year. Sick term infants or the smaller and more
vulnerable preterm infants are subjected to many more frequent and invasive
procedures . This pain or distress may be repeated as in the case of venepuncture or
heel prick, or be prolonged as in babies who are mechanically ventilated.
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Clinicians now accept that newborn infants can and do experience pain and there is a
large amount of literature examining the problem of acute procedural pain in the
newborn. There are, however, ongoing difficulties in the detection of pain in the
neonatal period. In the care of older children and adults, doctors rely on self-report
indicating that a person is in pain. This is not applicable in preverbal infants. The
only means of identifying pain in the newborn is by careful observation of
behavioural and physiological parameters. In the preterm infant, the limited
repertoire of behavioural responses makes this challenging though facial responses
appear to be good indicators of acute pain. In addition, there is always likely to be a
degree of subjectivity in assessment ofbehaviour.
In an attempt to facilitate and standardise pain recognition and assessment, a number
of scoring systems and scales for acute pain have been developed and validated for
use in term and preterm infants3;9;1°. Some deal with procedural pain, others are
designed to be used to assess postoperative pain. Most rely on facial responses,
though some also include physiological parameters such as changes in heart rate and
oxygen saturation11'12. Although physiological changes are objective and may be
useful when accompanied by changes in facial expression, they are in themselves
non-specific. For example, the increased heart rate or decreased oxygen saturation
observed when a baby is in pain may equally be due to pyrexia or respiratory disease
respectively and similar changes not infrequently accompany non-painful
interventions.
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There has been only limited investigation of the physiological and behavioural
effects of chronic or subacute pain in the newborn population. There is at present no
simple clinical scoring system for chronic pain or distress and no recognised
physiological indicator that can be used to assist with the identification and
management of chronic pain in infants undergoing neonatal intensive care.
Heart rate variability is known to be reduced in sick preterm infants compared with
well infants13"15. This may, in part, be due to the effects of chronic pain and stress
associated with mechanical ventilation and other necessary interventions during
intensive care. Increased heart rate and reduced heart rate variability have also been
demonstrated in infants undergoing acutely painful procedures such as
venepuncture1^17. The effects of analgesia and withdrawal of analgesia on mean
heart rate and heart rate variability in preterm newborn infants have not been
investigated.
The cutaneous flexor withdrawal reflex has been used by investigators in the field of
1 8
neonatal pain as a research tool . Previous work has shown that it correlates well
with the perception of pain. It has been used to examine effects of topical anaesthesia
in infants but its use as a clinical measure of the effects or adequacy of analgesia in
ventilated neonates has not been investigated19.
This study aims to explore the relationships between acute/procedural and sub
acute/chronic pain, heart rate variability and analgesia in premature infants in the
3
intensive care situation. It also aims to assess whether mean heart rate, heart rate
variability or the cutaneous flexor withdrawal reflex are clinically useful indicators
of pain or opiate withdrawal in preterm infants.
4
CHAPTER 2
AIMS OF THE RESEARCH
The broad objectives of this study were:
To investigate the effects of analgesia in preterm newborn infants in two different
situations
1. In ventilated infants - subacute/chronic pain/distress (morphine analgesia)
2. In infants undergoing ophthalmological examination as screening for
retinopathy of prematurity - acute pain/distress (sucrose analgesia)
The specific objectives of this study were:
1. to examine differences in mean heart rate, heart rate variability and the
cutaneous flexor withdrawal reflex between infants randomised to receive
morphine or placebo for intensive care
2. to compare two different methods of heart rate monitoring in preterm
infants
5
3. to examine differences in mean heart rate and heart rate variability
between infants randomised to receive sucrose or placebo for
ophthalmological examination
4. to assess whether mean heart rate, heart rate variability or the cutaneous
flexor withdrawal reflex are clinically useful indicators of pain or opiate
withdrawal in preterm infants
6
CHAPTER 3
PAIN IN THE NEWBORN
3.1 DEFINITIONS
The International Association for the Study of Pain (LASP) defines pain as "an
unpleasant sensory and emotional experience associated with actual or potential
tissue damage or described in terms of such damage"20. According to this definition,
the perception of pain is subjective and is dependent both on previous experience and
self-report.
The term 'nociception' describes the behavioural and physiological effects induced
by a noxious stimulus, without reference to the associated psychological and
emotional responses. Since newborn infants neither have prior experience of pain nor
the ability to communicate, nociception more accurately describes the phenomenon
of acute pain in the neonate. However, the terms are frequently used interchangeably
in literature on the subject of neonatal pain.
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'Stress' refers to adaptive responses generated by external occurrences or internal
factors. Such adaptive responses are normal responses. Stress will produce 'distress'
only if it persists and leads to maladaptive behaviour.
The issue of chronic pain and distress in infants presents difficulties when
considering the newborn. Previously, chronic pain has been defined as pain lasting
for six months or recurring periodically over a six-month period. The IASP now
recognises chronic pain as that which persists for longer than one month beyond the
normal healing time for an injury or disease. Even this shorter period of time cannot
be used in the neonatal period, which by definition is the first 28 days of life. Whilst
such classifications are useful in the study of pain generally, much of the
terminology is more suited to adults who are able to articulate their feelings. There is
no definition entirely appropriate to describe ongoing pain or distress in the neonate,
which may be present for hours or days rather than the weeks and months. For the
sick, preverbal infant, it may be more appropriate to consider pain according to both
the cause and likely duration of the insult. Pain resulting from an invasive procedure
is immediate, often lasting only seconds or minutes, whereas the pain potentially
caused by ongoing inflammation is likely to persist for hours or days. Detection and
management of these contrasting phenomena will differ, so a distinction must be
made.
For the purposes of this discussion, the pain induced by a defined invasive procedure
will be referred to as 'acute' or 'procedural' pain. Pain which results from a
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condition such as inflammatory disease or an intervention likely to lead to prolonged
discomfort lasting for hours or longer, will be referred to as 'chronic' pain.
3.2 AN HISTORICAL PERSPECTIVE
Attitudes of medical professionals towards the issue of pain in newborn infants have
changed markedly with the passage of time. Until the early 20th century, it was
believed that children and infants experienced more pain than adults, with several
medical texts of the time making reference to hyperalgesia in infants and the
recognition of pain by facial expression.
However, a change in thinking occurred as a result of research into the developing
nervous system. In 1872, Paul Emil Flechsig noted that although both myelinated
and unmyelinated fibres were present, only myelinated fibres appeared to be fully
functional. He suggested that complete myelination is required for perception of pain
and this led to the widespread belief that the immature nervous system of newborn
infants was not sufficiently developed to render them capable of experiencing pain.
More recently, L.I. Swafford and D. Allen stated that "pediatric patients seldom need
medication for the relief of pain after general surgery. They tolerate discomfort
9 ?2 1well" . At this time, it was common for babies and young children to undergo
surgical procedures without anaesthesia or pain relief. Additional 'proof that babies
9
did not feel pain was the fact that they had no memory of painful experiences in early
childhood. Concerns about appropriate opiate dosing and the possibility of
encouraging opiate addiction in paediatric patients together with the belief that
infants react adversely when given opiates have also played a part in the reluctance
22
of physicians to prescribe adequate analgesia .
The anatomy of the developing fetal and neonatal nervous system has been clarified
by extensive research in animals and humans. It is now clear that cutaneous sensory
receptors begin to appear early in foetal life and continue to spread throughout all
skin and mucous membranes until the 20th week23'24. Skin in the newborn period has
a greater density of nociceptive nerve endings than is found in adults23. At around 8
to 10 gestational weeks, development of neural connections between the periphery
and the dorsal horn of the spinal cord begins to occur26. Formation of synaptic
connections and neurotransmitter vesicles continues to complete the development of
the dorsal horn by around 30 weeks of gestation. Lack of complete myelination of
nerve fibres has been suggested as an indicator of nervous system immaturity and the
lack of ability of neonates to perceive pain21;27. In adult peripheral nerves, some
transmission of nociceptive impulses occurs via unmyelinated and thinly myelinated
25fibres . Incomplete myelination of nerve fibres leads to slower conduction of
impulses, rather than absence of conduction. In infants, this slower conduction is
offset by the relatively short distance travelled by impulses in babies as compared
with adults. Myelination is completed during the second and third trimesters. The
cerebral cortex starts to develop at 10 gestational weeks. This continues until term
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and beyond with growth, differentiation and branching and migration of neurones.
Nociceptive pathways from the periphery to the cortex pass through the thalamus,
therefore maturity of neural connections in the thalamus is necessary for pain
perception. Thalamocortical connections are completed by 20 - 24 weeks of
gestation28. Electroencephalograms (EEGs) have been studied in fetuses and
extremely preterm infants in an attempt to define cerebral function in physiological
terms. A primitive EEG characterised by intermittent bursts is seen from 20 weeks of
gestation. The EEG patterns mature over the next few weeks of gestation. By 28
weeks, EEG patterns are sufficiently defined as to make observation of identifiable
sleep-wake patterns in fetuses possible . There is also evidence to suggest that
fetuses can mount physiological stress responses in utero. Interventions that would
be expected to be painful for the fetus such as those which involve piercing of the
abdomen cause a significant rise in production of Cortisol and noradrenaline, even in
early gestation. Procedures that would be unlikely to be painful do not induce such a
29.30
response ' . This evidence all points to the fact that newborn babies, even those
born prematurely, do have the anatomical and functional requirements to allow
perception of pain, although further development occurs during the postnatal
period25.
Considerable research in rats and human infants has been carried out to explore the
cutaneous flexor withdrawal reflex. This is present in preterm infants from 26 weeks
gestation26'31. It has been shown to correlate well with pain threshold and has been
used as a measure of sensation in newborn infants. Investigation has shown that the
11
threshold for the cutaneous flexor reflex is very low in newborns and increases with
18 ...
increasing gestational age, rather than postnatal age . Repeated stimulation in
preterm babies results in sensitisation characterised by increase in the force of
withdrawal with repeated stimuli18. This occurs in infants of below about 30 weeks
gestation, but is seen less often with increasing gestational age. In contrast, in infants
of more than 34 weeks gestation, repeated stimulation leads to habituation and
decrease in the response, rather than sensitisation. The concept of wind-up has been
well described in animal studies32 and may also be important in human neonates.
This describes the phenomenon where repeated painful stimuli are followed by
exaggerated responses to mild, non-noxious stimuli that would not usually be
perceived as painful.
In spite of increasing evidence that newborn babies experienced pain, perhaps even
more acutely than older children and adults, routine analgesia for painful procedures
was rarely used. Although it had been recognised by some that pain in infants and
children frequently went untreated or, at best, under-treated33;34 it was not until the
mid to late 1980s that important work by Anand et al brought the subject into the
public arena. Controversy and outcry arose because babies undergoing surgery as
control subjects received no analgesia; this was standard practice at that time. The
study showed that preterm infants were able to mount a significant hormonal and
metabolic stress response to surgery and that this response could be attenuated by the
use of opioid analgesia (fentanyl) during surgery1 ;35. It was also noted that infants
receiving analgesia had fewer complications following surgery.
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Research in the field of neonatal pain assessment has advanced considerably in
recent years, with work concentrated mainly on the area of acute pain. Behavioural
and physiological responses of infants undergoing painful procedures have been
documented and a number of tools for the detection of pain have been developed and
validated10'12'36"42. Knowledge of the pharmacokinetics of opioid and other analgesics
in infants has been greatly increased.
The problem of chronic pain in the neonatal period has been less well investigated43.
There is, at present, no recognised physiological indicator that can be used to assist
with the identification and management of chronic pain in infants undergoing
intensive care.
3.3 PAIN IN THE NEONATAL INTENSIVE CARE UNIT
Advances in obstetric and neonatal care during recent years have led to the survival
of increasing numbers of extremely premature and low birth weight infants with
gestational ages as low as 23 weeks. These tiny patients, undergoing life-saving and
essential therapy during neonatal intensive care are, of necessity, subjected to a wide
range of stresses and interventions. Older children or adults would certainly perceive
many of these as painful or distressing. We cannot and will never know precisely
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how the newborn baby perceives these interventions, but it is reasonable to suppose
that those procedures reported as painful or distressing by articulate adults, would be
similarly perceived by the preverbal infant.
Procedures causing direct tissue damage are common during the first hours and days
of life for a preterm or seriously ill term baby. Such procedures include
venepuncture, heel stick, arterial line insertion, chest drain insertion, lumbar puncture
and suprapubic aspiration of urine. There can be little doubt that these invasive
events cause acute pain and warrant consideration of specific analgesics appropriate
to the degree of invasiveness of the procedure.
A number of other less invasive procedures are commonly performed such as
endotracheal intubation and suction, nasogastric tube insertion and umbilical venous
and arterial catheterisation and ophthalmological examination. Whilst these do not
usually involve tissue damage, they are likely to produce varying degrees of
procedural pain or discomfort.
Essential nursing interventions such as placement, repositioning and removal of
monitoring electrodes or probes and handling associated with nappy or linen changes
are regular occurrences. Such interventions are often undertaken in 'clusters'
following more invasive procedures thus allowing longer rest periods for the infant.
However, bearing in mind the phenomena of sensitisation and 'wind-up' previously
described, it is possible that these relatively benign procedures might be perceived as
14
painful if approached in this way. Studies reporting changes in transcutaneous
oxygen and pain behaviours in infants associated with "nonpainful" procedures
i • • 44-46
support this view
There are a number of conditions that commonly affect newborn babies and which
may cause chronic pain. Preterm infants are at particular risk of necrotising
enterocolitis, whilst infants born at any gestation may develop illnesses such as
septicaemia, meningitis, pneumonia or osteomyelitis. All of these conditions will
induce an inflammatory response within tissue, likely to cause pain that may persist
for hours, days or weeks until the disease has run its acute course. Intraventricular
haemorrhage affects a significant number of extremely premature infants and it is
possible that this condition may cause pain if bleeding affects the meninges.
The sickest and most premature infants usually require mechanical ventilation.
Adults recall that having endotracheal or gastric tubes in the mouth or nose is a major
source of stress during their stay in an intensive care unit47"49. Although the sensation
may not be specifically described as 'pain', it is likely that the experience of
prolonged mechanical ventilation is also unpleasant and a source of ongoing distress
for the newborn baby. Therapeutic paralysis makes detection of pain even more
challenging and may in itself cause distress, as may tissue oedema that is often seen
in this group of infants, particularly those receiving muscle relaxant drugs.
15
3.4 PHYSIOLOGICAL AND BIOCHEMICAL RESPONSES
TO PAIN
Invasive or acutely painful interventions in neonates are accompanied by a number
of measurable physiological and biochemical responses many of which are
undesirable. Significant changes have been demonstrated by investigators in
association with many procedures commonly carried out during intensive care of the
newborn. These include heel prick50'51, venepuncture52, circumcision5"55,
endotracheal intubation56'57 and endotracheal suction58'59. Physiological changes
described include increase in mean heart rate, change in respiratory patterns, increase
in blood pressure and decrease in oxygen saturation or transcutaneous oxygen levels.
Increase in skin conductance60 and increased 'emotional' palmar sweating61 have
also been shown in term newborn infants exposed to heel prick, but do not occur in
those born before 36 weeks gestation.
Many of these physiological parameters are routinely monitored in premature infants
undergoing intensive care and as such, might be useful in the day-to-day evaluation
of pain. However, most physiological responses are not specific to pain and change
in response to other interventions that are not judged to be painful. By themselves,
therefore, these measures are of limited value in pain assessment.
Newborn infants mount a significant hormonal and metabolic stress response to
painful stimuli. Much of the work on this subject was carried out on babies
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undergoing circumcision or surgery. Gunnar showed a marked increase in Cortisol
levels in infants after circumcision without anaesthesia62. In neonates having surgery
with minimal anaesthesia, Anand demonstrated a marked catecholamine response at
the end of surgery1, increases in lactate and pyruvate and suppression of insulin
secretion. Release of adrenaline at the time of surgery is thought to play an important
part in initiation of other changes seen post-operatively in babies such as
hyperglycaemia1. These metabolic and hormonal responses are attenuated by deep
anaesthesia and analgesia35;63;64. There is little literature addressing more minor
painful procedures such as endotracheal or oral suction65 and heel prick66.
3.5 BEHAVIOURAL RESPONSES TO PAIN
Behavioural indicators of pain in newborn infants have been extensively studied.
Crying, changes in facial expression, gross motor movements and changes in
behavioural state and sleep-wake cycles have all been evaluated.
Crying is the newborn baby's most effective method of communication with adults.
Studies using spectrographic analysis of pre-recorded cries show that cries can be
classified and those reflecting different types of distress can reliably be recognised
by experienced observers67'68. Patterns of crying have also been shown to correlate
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with intensity of pain in infants at circumcision69. Cry duration is less good as an
indicator of pain intensity70.
Facial expressions associated with exposure to pain are well characterised. Facial
responses include brow bulge, eye squeeze, deepening of the naso-labial furrow,
open mouth, vertically and horizontally stretched mouth and taut, cupped tongue.
These facial features are demonstrated in premature infants71'72 and term infants73
71
although the younger the gestational age in preterm infants, the less the response .
Guinsburg et al demonstrated that there may also be a difference in facial indication
of pain between male and female infants, with females showing greater facial
expression than males74.
Body activity caused by the pain of heel prick has been examined. Infants born at
term show more whole body activity in response to pain than do premature infants71.
Behavioural states in term and near term infants occur in cycles75. In premature
infants, states are less well regulated. Pain in term infants has been shown to disrupt
behavioural state and sleep-wake cycles. Emde et al reported that a prolonged period
of non rapid-eye-movement sleep followed circumcision76. Other studies have shown
increased wakefulness following circumcision77. Minor painful procedures have been
shown to increase the behavioural state in neonates78. The behavioural state of an
infant prior to a painful procedure has also been shown to affect facial activity in
response to the painful stimulus68'73. Behavioural states are difficult to accurately
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assess and are also altered by other conditions such as severe illness and neurological
disorders or injury. The usefulness of such assessment in pain measurement is
therefore limited.
3.6 ASSESSMENT OF PAIN
Assessment of pain is the key to appropriate management of pain. Without accurate
and reliable means of assessing pain, it is impossible to evaluate the need for or the
effectiveness of intervention. In the absence of self-report, the difficulties of
identification and measurement of pain in babies are many. It is further limited by the
narrow behavioural repertoire, particularly of premature infants and the lack of
specificity of the associated physiological responses. This has led to the development
of a number of clinical tools in the form of scoring systems for the assessment of
pain and distress in neonates. For such a tool to be useful, it must enable the observer
to detect the presence of pain and describe or grade the intensity of the pain. The
measures included in any pain assessment score must be well defined and validated
such that observations are comparable between observers and reliable between
infants. The feasibility of its use in the clinical setting is dependent on its simplicity
and ease of execution.
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Most of the work, to date, has centred upon the area of acute pain. Both behavioural
and physiological indicators of pain have been incorporated into pain assessment
scores. Some have chosen to use a unidimensional approach, using a single type of
pain indicator. Behavioural indicators, including facial activity, which appears to be
the most specific of pain indicators in infants, form the basis ofmost unidimensional
scoring systems. Although unidimensional measures have been useful in pain
research, no single measure is reliable, valid, sensitive and specific and most
unidimensional scores are not clinically useful for the recognition and assessment of
pain in the newborn. Other investigators have combined behavioural and
physiological indicators to produce multidimensional scores.
3.6.1 Scores for Assessment of Acute Pain
3.6.1.1 Unidimensional Measures
The Neonatal Facial Coding System (NFCS)67'73 uses the characteristic facial
expressions associated with pain (brow bulge, eye squeeze, nasolabial furrow, open
lips, stretch mouth, lip purse, taut tongue, chin quiver and tongue protrusion) to
assess the presence of pain. This score has been validated and its feasibility as a
clinically useful tool has been tested9.
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The Infant Body Coding System (IBCS)79 is a behavioural tool using gross motor
movements in infants exposed to acute painful stimuli. Movements of the hand, foot,
arm, leg, head and torso are observed and recorded as being present or absent.
The Children's Hospital ofEastern Ontario Pain Scale (CHEOPS)80 was designed
for use postoperatively in children over 1 year. It was adapted to form the Modified
Behavioural Pain Scale (MBPS)81 for use in infants from 4-6 months, but has not
been validated in neonates. This scale uses 3 indicators including facial expression,
cry and gross body movements.
The Liverpool Infant Distress Scale (LIDS)39'82 was developed to assess the degree
of distress due to postoperative pain in infants. It uses eight behavioural categories,
including facial expression, quality and quantity of crying, scoring each on a scale of
0 to 5.
In France, the Douleur Aigue du Nouveau-ne (DAN)41 has been validated as a
discriminator of pain, but has not been proven to grade intensity of pain. The DAN
scores pain from 0-10, evaluating facial expression, limb movements and vocal
expression. It has been used in research to assess the effectiveness of analgesia83.
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3.6.1.2 Multidimensional Measures
The Neonatal Infant Pain Scale (NIPS)36 was also adapted from the CHEOPS80. It
utilises five behavioural and one physiological (breathing patterns) measure, each
indicator scored on a 2 or 3-point scale. The scale has been validated and has been
compared with other pain scales42. It is used mainly in research.
The CRIES (Crying, Requires oxygen for saturation above 95%, Increased vital
signs, Expression and Sleeplessness)37 is a postoperative score using five
physiological and behavioural indicators giving a score of 0 - 10. The score was
validated in a group of 24 babies.
OA
The Distress Scale for Ventilated Newborn Infants (DSVNI) assesses the response
to pain in ventilated neonates. This scale was developed using elements from five
other previously developed scoring systems (Neonatal Behavioural Assessment
Scale(NBAS)85, the Assessment of Preterm Infants' Behaviour(APIB)86, the
NFCS67'73 the IBCS79 and the Gustave-Roussy Child Pain Scale87;88. It includes
measures of both physiological and behavioural responses, but is only useful in this
small group of infants and has not been validated.
The Scale for Use in Newborns (SUN)42 consists of three behavioural (movement,
tone, face) and four physiological measures (neurological state, breathing, heart rate,
blood pressure). Each category is scored from 0-4 with 2 being normal. The SUN's
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validity and clinical utility were established during comparison with two other
scales42.
The Premature Infant Pain Profile (PIPP)12 is perhaps the most extensively validated
pain score for use in both term and preterm infants. It takes into account seven
indicators, of which three are behavioural (brow bulge, eye squeeze, nasolabial
furrow), two physiological (heart rate and oxygen saturation) and two contextual
(gestational age and behavioural state). Each indicator is evaluated using a four-point
scale. The total possible score for infants of less than 28 weeks gestation is 21 and
for those of greater gestational age is 18. For both groups, a total score ofmore than
12 indicates moderate to severe pain, while a score of less than 6 indicates little or no
pain. The validity and inter- and intra-rater reliability of the PIPP have been
established in the clinical situation89 and it has been used in research studies to assess
the efficacy of pain relief interventions90.
The Comfort Scale91 was designed specifically for use in infants and children up to
the age of 2 years in the intensive care situation. It has been shown to measure
reliably the adequacy of sedation in these patients92. It was compared with the NIPS
and SUN to establish its validity and clinical use, but was found to be the most
complex of the scores and difficult to use42.
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3.6.2 Scores for Assessment of Prolonged Pain
The EDIN (Echelle Douleur Inconfort Nouveau-ne)10 represents the first scoring
system to be developed for the assessment of prolonged pain in preterm newborn
infants. It is a unidimensional tool, using only behavioural indicators. Facial activity,
body movements, quality of sleep, and quality of contact with nurses and
consolability are evaluated as measures of pain. Each measure is scored on a four-
point scale of 0 - 3. The study to validate the EDIN involved 76 preterm infants.
Scores in extreme situations, before and after analgesic therapy were compared to
establish validity of the scoring system. Inter-rater reliability was found to be
acceptable.
The N-PASS (Neonatal Pain, Agitation and Sedation Scale)93 is a scale that is
currently being developed and is in the early stages of evaluation in the clinical
setting, but as yet there are no published data relating to N-PASS. The score uses
crying and irritability, behavioural state, facial expression, extremities tone and vital
signs (heart rate, respiratory rate, blood pressure and oxygen saturation) as
indicators. Each indicator is evaluated on a score of-2 - +2.
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3.7 MORPHINE ANALGESIA IN NEONATAL INTENSIVE
CARE
A variety of systemic analgesic and sedative drugs are available for use in the
newborn. Opiate analgesics are probably the most widely used in neonatal intensive
care94;95. A number of opioids including morphine, diamorphine, fentanyl, alfentanil
and sufentanil are used in treatment of neonates undergoing surgery or intensive care.
Morphine is the oldest and most extensively studied in all ages and, as such, is also
the most frequently used clinically. Since more recognition has been given to the
problem of neonatal pain, its use in newborn intensive care has dramatically
increased.
Morphine is an extract of opium and analgesia is mediated principally by p-opioid
receptors. It acts at the receptors to hyperpolarize cell membranes and reduce
neuronal activity.
3.7.1 Morphine Pharmacokinetics and Pharmacodynamics
Information on pharmacokinetics of morphine is limited. This is perhaps due to the
need for repeated blood sampling in such studies that presents a problem in the
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neonatal population. In general studies have included small numbers of infants and
results show great variation.
Plasma protein binding of morphine varies with age. In the premature infant, less
than 20% is protein bound96.
Studies to examine the volume of distribution ofmorphine vary in the ages of infants
studied. Their results are conflicting. Some report similar steady state concentrations
in preterm and term infants97 while others report great variation depending on the
postnatal age in preterm infants96.
Morphine is metabolised by the liver via glucuronidation. Its metabolites are
morphine-6-glucuronide and morphine-3-glucuronide, which are excreted by the
kidneys. The rate of metabolism depends on the age of the patient and
glucuronidation is less efficient in the newborn98"101. Morphine-6-glucuronide is a
potent analgesic and has slow clearance compared with morphine. Adults and older
children excrete less than 10% morphine in unchanged form, whereas sick neonates
excrete much larger amounts.
Clearance of morphine depends on age, but there is also large inter-individual
variation. The elimination half-life in preterm infants is 10-20 hours, decreasing to 1-
2 hours in preschool children and settling at 2-4 hours in adulthood. Renal failure
will lead to accumulation ofmorphine and its metabolites.
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Plasma concentrations of morphine that are appropriate for analgesia are difficult to
determine, because of the problems of differentiating between analgesia and
sedation. Study results vary, reporting values of between 12 and 65ng/ml as effective
concentrations102. This is indicative of the difficulties in performing such studies.
3.7.2 Tolerance
Tolerance refers to a decrease in the pharmacological effects of a drug with repeated
administration or the requirement for an increase in dose to maintain the same
clinical effect102. Opioid tolerance is due to adaptation of neuronal cells within the
central nervous system. Research suggests that tolerance may develop more rapidly
with continuous opiate infusions than with intermittent doses104;105. There is little
information available to indicate the length of treatment required before development
of tolerance in the preterm neonate.
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3.8 OPIATE WITHDRAWAL IN PRETERM INFANTS
Little literature is available relating to the effects of discontinuation of therapeutic
doses of opiates in preterm neonates. Opiate withdrawal effects are well documented
in adults and children106'107. Term infants whose mothers have used opiate drugs
during pregnancy are commonly known to display an identifiable constellation of
signs and symptoms known as the neonatal abstinence syndrome108'109. Validated
scores are used to grade the features of neonatal withdrawal in such circumstances109.
Withdrawal behaviour has been studied in the past in infants exposed to opiate
medication during extracorporeal membrane oxygenation104. This study used a
modification of the Neonatal Abstinence Score to evaluate withdrawal and, in these
term infants morphine was shown to be associated with fewer withdrawal effects
than fentanyl. Since the behavioural repertoire of sick preterm neonates often differs
from that of term babies, it is possible that they might also exhibit different types of
response to opiate withdrawal or that the signs might differ in quantitative or
qualitative terms.
The question of whether cessation of therapeutic doses of opiates in sick premature
infants causes a recognisable withdrawal syndrome remains to be answered. Preterm
infants are a difficult group to assess due to their limited behavioural repertoire and
the relative inexperience of clinicians, particularly where infants of extremely early
gestation are concerned. These babies are frequently very sick and receive multiple
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therapies, usually including mechanical ventilation. A number of the elements of
accepted scoring systems are therefore more difficult to apply, or lack relevance for
the premature neonate in the intensive care setting; for example, sweating, sneezing,
regurgitation, loose stools, fist sucking and excoriation of skin. Most of these
features are unlikely to be observed in babies who are ventilated and in whom enteral
feeds have not yet been introduced. It is likely, therefore, that attempts to assess
withdrawal effects in this vulnerable population are often inappropriate and
inadequate.
In order to prevent the onset of potential, but poorly defined withdrawal phenomena,
opiate drugs are weaned over a variable period of time in some neonatal units.
However, this is not a universal practice, with some clinicians having anxieties about
continuing even low-dose opiate infusion in spontaneously breathing babies. There is
no published evidence to suggest that any weaning regimen is optimal. The
identification of a reliable physiological indicator of opiate withdrawal in this group
of infants would allow evaluation ofweaning protocols.
The effects of opiate withdrawal on mean heart rate and heart rate variability have
not been explored. It would be expected that patterns associated with opiate
withdrawal would become evident shortly after discontinuing therapy or during the
weaning phase and then resolve gradually over time as the drug is excreted.
Identification of a clear difference in heart rate or heart rate variability between the




(NEUROLOGICAL OUTCOMES AND PRE-EMPTIVE
ANALGESIA IN NEONATES)
4.1 STUDY DESIGN AND METHODS
The N.E.O.P.A.I.N. Multicentre Trial was a randomised, double blind, placebo
controlled trial investigating the use of routine morphine infusions in preterm
ventilated infants. Primary outcomes to be investigated were mortality and poor
neurological outcome. A total of 900 infants were recruited to the study in 16
neonatal intensive care units in North America, Scandinavia, France and Scotland.
Babies born at 23-32 weeks gestation were randomised to receive either continuous
low-dose morphine infusion or placebo (dextrose 5%) from the time of intubation for
the duration of the time spent on a ventilator (minimum 24 hours) up to a maximum
of 14 days. Morphine infusion rates were stratified by gestational age. A loading
dose of lOOmcg/kg was used. Babies of 23-26 completed weeks of gestation received
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maintenance doses of 1 Omcg/kg/hour, those of 27-29 weeks received 20mcg/kg/hour
and babies of 30-32 weeks of gestation, received 3Omcg/kg/hour.
4.2 N.E.O.P.A.I.N. STUDY POPULATION (SCOTTISH
CENTRE)
The Scottish arm of the N.E.O.P.A.I.N. study was conducted on the Neonatal Unit of
the Simpson Memorial Maternity Pavilion, Edinburgh, United Kingdom, between 1
August 2000 and 31 December 2001.
Of around 7000 babies delivered each year within the area served by the Neonatal
Unit, approximately 550 infants are admitted to the Neonatal Unit, of whom 180 will
require ventilation. During the study period, 210 infants between 23 and 32
completed weeks of gestation were admitted to the neonatal unit and were eligible to
enter the N.E.O.P.A.I.N. study on the basis of gestational age. Of these, 95 (45%) did
not require mechanical ventilation and a further 25 (12%) babies were ventilated for
less than 24 hours. 28 babies were excluded for other reasons including congenital
abnormalities, severe birth asphyxia or maternal opiate abuse. Parental consent was
refused in 18 ventilated babies who would otherwise have been eligible to enter the
study. A total of 44 infants were recruited to the N.E.O.P.A.I.N. Multicentre Study
(Scottish Centre). 52% of the babies were male. The median gestational age of the
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babies included was 28 weeks (range 23-32) and the median birth weight was 1022 g
(range 500-1935). 22 babies were entered into each treatment group.
4.3 ADDITIONAL INVESTIGATION OF INFANTS
Babies enrolled into the N.E.O.P.A.I.N. study form a unique cohort from a
randomised blinded study comparing the effects of treatment with morphine versus
placebo. Research into pain in newborn babies is an emotive area. Some believe that
all babies undergoing intensive care with ventilation should receive analgesia despite
the lack, to date, of published data regarding short and long-term benefits of
analgesia in this group. Given the difficulties and controversy surrounding pain and
analgesia in the newborn, it may be inappropriate to conduct a similar study again.
This group of preterm babies, therefore, provides an ideal opportunity to investigate
other aspects and the effects of pain and analgesia.
We used the opportunity of participation in the N.E.O.P.A.I.N. trial to investigate
heart rate variability and the cutaneous flexor withdrawal reflex in babies randomised
to receive continuous low-dose morphine infusion or placebo. 38 of the 44 babies
recruited to the N.E.O.P.A.I.N. were involved in this additional investigation.
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4.4 ETHICS AND CONSENT
The Lothian Research Ethics Committee granted approval for this research. Verbal
and written information about the multicentre study and the local additional research
interventions was given to all parents. Parents were given the option of enrolling
their baby in the N.E.O.P.A.I.N. Study without taking part in the local research, but
no parent declined the extra measures. Informed, written consent for additional
monitoring of heart rate using a Holter monitor and testing of the cutaneous flexor
withdrawal reflex using von Frey hairs was obtained from parents of all infants
enrolled in the N.E.O.P.A.I.N. Study.
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CHAPTER 5
EFFECTS OF ANALGESIA ON MEAN HEART RATE
AND HEART RATE VARIABILITY IN PRETERM
VENTILATED INFANTS
5.1 BACKGROUND
A number of physiological variables have been used in term infants to assess pain.
The changes in heart rate and transcutaneous oxygen partial pressures or oxygen
saturation have been used as measures of pain in conjunction with behavioural
measures. A simultaneous rise in heart rate and fall in partial pressure of oxygen is
seen with procedures that involve tissue damage11'110. These measures have been
used to evaluate the use of topical anaesthetic111 and sucrose112 analgesia for heel
prick. In preterm infants and in ventilated infants of any gestation, the range of useful
and relevant pain indicators is more limited. Emotional sweating has been used as an
indicator of pain in infants exposed to heel prick61 but this does not occur in babies
of less than 36-37 weeks gestation. Cry, which has frequently been used as an
indicator of pain, is difficult to assess in infants who have an endotracheal tube in
place. An additional difficulty with all physiological measures is that absolute values
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and change from baseline in these values are not specific for pain. In the case of heel
prick, an increase in heart rate is observed with skin preparation, although the
increase is greater with the invasive part of the procedure71. In preterm babies,
assessment is further complicated by the variation in physiological parameters
associated with increasing gestational age.
The variability of physiological parameters such as heart rate, respiratory rate, and
oxygen and carbon dioxide tensions of the blood has been investigated as a measure
of pain. Mcintosh et al showed that variability of these parameters seemed to be
more discriminating for distress caused by heel prick than the absolute heart
rate113'"4. Of the four parameters, variability of heart rate appeared to provide the
most useful information about pain.
Heart rate variability is a measurement of beat-to-beat changes in heart rate. The
normal variability in heart rate is due to the synergistic action of the two branches of
the autonomic nervous system on the sinoatrial node. These act in parallel through
mechanical, neural, humoral and other physiological mechanisms to maintain
cardiovascular parameters in optimal ranges and to react appropriately to external or
internal stimuli. In normal healthy individuals the heart rate varies constantly and an
estimate of heart rate at any one point in time will represent the net effect of slowing
by the parasympathetic nerves and acceleration by the sympathetic system. It is
thought that greater increases and decreases in the heart rate of an individual
represent a "healthier" state and better capacity to respond to demands presented by
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stressors and the external environment. It might be anticipated therefore, that
measurement of heart rate responses to painful events could provide a useful
additional window into the complexity of pain reactivity in the infant.
The simplest measure of heart rate variability in the time domain is the standard
deviation about the mean heart rate. This will reflect all components of variability
during the time span over which measurements are made, but will be dependent on
this length of time. This method was used by Mcintosh et al113 ll4, but more
complex methods have been used by other researchers. In the frequency domain,
spectral analysis identifies changes in the power spectra of heart rate fluctuations in
the low and high frequency ranges and is a more precise means of quantitatively
assessing the function of the autonomic nervous system15'115.
Heart rate variability has been extensively studied in the fetus, newborn infant, child
and adult. Fetal heart rate variability has been used for many years as a measure of
fetal well-being and reduction in this variability is recognised as a reliable indicator
of fetal distress. Postnatally, spectral analysis has been used in healthy term 116-118
and preterm ,4'119'120 newborn infants to identify normal patterns of heart rate
variability and factors that influence these patterns. Cabal et al showed that, in
preterm infants, heart rate variability is inversely related to heart rate and related to
postnatal age14.
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Variability has been shown to increase with increasing gestational age,
discriminating in particular between groups of preterm and term infants117.The
effects on heart rate variability of a number of disease states and therapeutic
interventions have been investigated. Studies have shown decreased heart rate
variability in infants with respiratory distress syndrome and that persistent reduction
in variability is associated with an increased incidence of mortality13. Heart rate
variability has been shown to increase as respiratory distress improves 15. Mechanical
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ventilation in itself does not appear to exert an influence on variability .
Investigation of heart rate variability in infected infants has shown that these babies
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display abnormal heart rate characteristics when compared with non-septic infants .
Most studies of preterm infants have involved babies of gestational ages greater than
27 weeks. There is little information regarding heart rate variability in extremely
premature infants of 23 - 26 weeks' gestational age. Heart rate variability decreases
with increasing age, starting during childhood. The study of heart rate variability in
older children has included attempts at defining normal patterns at rest and with
exercise, highlighting the difficulties in obtaining accurate measurements in this age
group123'124. Heart rate variability in children has also been studied in respiratory and
cardiovascular abnormalities or disease processes125'126. The relationship between
heart rate and emotional or psychological states has also been investigated127'128
suggesting that heart rate variability decreases in the face of psychological stress.
Patterns of variability in adults also alter with disease states and changing emotions.
Much of the work in adults has been centred on the area of cardiovascular function in
ischaemic heart disease and diabetes. Myocardial infarction has been shown to
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produce a decrease in heart rate variability and reduction in variability in patients
with heart failure is predictive of an increased risk of sudden death129. Decreased
heart rate variability occurs in diabetic autonomic neuropathy130 and is associated
with higher mortality131. These studies are in keeping with the view that increased
physiological variability reflects a state of greater well-being.
There are no data regarding the influence of pain on heart rate variability in adults
and in the studies looking at painful conditions such as angina pectoris, the specific
role of pain has not been addressed. Likewise, in children, there has been little work
on this subject although a recent study has examined heart rate variability in children
undergoing propofol anaesthesia for painful procedures. This study used spectral
analysis and the authors concluded that it is possible to obtain useful information
about the sympathetic response to pain from the low frequency power spectral
132data . For the most part, however, the investigation of pain and its effect on heart
rate variability has been confined to the neonate. In early studies the distress
associated with heel prick was shown to produce an increase in heart rate variability,
using the standard deviation of the mean heart rate as a measure but did not produce
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an increase in heart rate . Variability of other physiological parameters also
increased with the painful stimulus in this study as compared to a sham procedure.
Further work again used this method to highlight this response and to demonstrate
that the increase in variability could be attenuated by the use of an automatic spring-
loaded device rather than a conventional lancet for heel prick"4. Johnston et al
found different results using similar methodology. They saw both increased heart
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rate with heel prick and a differential response between sham and real procedures
and suggested that the response may be more related to the gestational age of the
infant than the nature of the stimulus133. Other studies have utilised frequency
domain analysis of heart rate variability to assess pain responses in preterm infants.
Using this method of assessment, increased heart rate and decreased variability were
seen with heel prick16. These changes were thought to reflect activation of the
sympathetic nervous system during the painful experience. When the procedure of
heel prick was analysed more closely, the differential changes in heart rate variability
indicated that the squeezing of the heel was the most stressful component of the
procedure134. Heart rate variability has also been used to evaluate the effectiveness of
treatment strategies for pain management. The response to venepuncture has been
studied using spectral analysis17. This study revealed a difference between groups
subjected to the procedure with and without the use of topical anaesthetic cream. The
placebo group showed a greater response in terms of increased heart rate and
decreased variability than the treatment group. Heart rate variability may be affected
by factors other than pain such as gestational age, behavioural state and previous
experience of pain, but has nevertheless been generally regarded as a useful measure
of the response of both term and preterm infants to noxious stimuli. Behavioural
indicators of pain probably remain the most sensitive, but do not always correlate
well with intensity of physiological responses135. It is possible that combination of
behavioural assessments with detailed measurement of variability of physiological
parameters may add to the understanding of the complex relationships between
different types of pain response.
39
The most appropriate method for assessment of heart rate variability will depend on
the situation in which it is to be used and the resources available. Although spectral
analysis is a more sophisticated method of measuring heart rate variability than
analysis of the standard deviation of the mean heart rate and is valuable as a research
tool, it is not, at present, suitable for routine use in the clinical setting. It is however,
relatively simple to incorporate displays of variability based on mean and standard
deviation of physiological parameters into computerised monitoring systems such as
the Badger System, used on the Neonatal Unit of the Royal Infirmary of Edinburgh.
If heart rate variability can provide a specific measure of pain, then this method is
much more likely to be effective as a clinical tool to provide a real time evaluation of
pain, distress and adequacy of analgesia. For these reasons, in the following work
described in this chapter and in the study relating to acute pain described in Chapter





5.2.1.1 The Badger System
Continuous monitoring using the Badger System is routine in all babies admitted to
the Neonatal Intensive Care Unit in Edinburgh. The Badger System is a real time
physiological intensive care monitoring system used at the cot side. Heart rate, blood
pressure, oxygen saturation and other physiological parameters are sampled and
recorded from the neonatal monitors at a rate of once per second
[www.clevermed.com]. Monitoring of the babies is commenced as soon as possible
after admission to the neonatal unit and is continued until the babies no longer
require intensive care. All clinical data collected using this system is available for
viewing at the cot side in the form of a trend graph as an aid to clinical management.
The data is also stored and can be accessed retrospectively for research purposes.
Data can be extracted and analysed using an additional computer program designed
for this purpose [Badger viewer, Alan Maxwell]. All infants included in this study
were monitored using the Badger System.
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5.2.1.2 The Braemar DL 700 Holier Monitor
A subset of infants was also monitored intermittently, using the Braemar DL700
Holter monitor [Braemar, Burnsville, MN, USA], This is a device designed for
continuous ambulatory ECG monitoring using 3 channels. The sampling rate of the
monitor is 128 per second. The data is recorded onto a flash memory card and can
then be downloaded onto a computer. Initially, the waveform data is stored in binary
format. This is then converted into text format using a computer program specifically
written for this function [Heartrate, Mansour Ahmadian]. A voltage threshold
detector is used to identify the peak voltages that represent the R waves of the ECG
and from this the beat-to-beat heart rate can be calculated.
5.2.2 Protocol for Monitoring of Infants
5.2.2.1 Badger System
36 of the 44 babies recruited to the NEOPAIN Trial were monitored as part of their
routine clinical management using the Badger System. Monitoring gel electrodes
(Blue Sensor electrodes, Medicotest) were placed on the baby's chest as soon after
arrival on the Neonatal Unit as was considered appropriate by nursing staff caring for
the baby. The time of commencement of recording depends upon clinical staff
entering basic demographic patient data into the system and activating the recording
42
system. This is usually done within the first few hours of a baby's admission to the
Neonatal Unit. Recording of data continued until a clinical decision was made to
discontinue.
5.2.2.2 Braemar DL 700 monitor
Additional monitoring using the Braemar DL700 Holter monitor was performed in a
subset of 29 babies. This involved connection of five additional gel electrodes to the
chest or back of the baby. Monitoring was carried out at the following times:
I. Prior to administration of the study drug
II. Daily for the duration of the maintenance dose of the study drug
III. Every 4 hours during the period ofweaning of the study drug for up to 48 hours
IV. Every 4 hours after discontinuation of the study drug
Monitoring of the infants was performed on each occasion for a minimum of 15
minutes. Where possible, this followed a period of at least 15 minutes undisturbed
rest and the infant remained undisturbed for the duration of the recording. In the less
stable babies, this was not always possible as very frequent nursing or medical
interventions were sometimes necessary. However, no period of recording was
included in the analysis if a painful or significantly distressing intervention was
required and performed during the time of recording. Where essential nursing or
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medical procedures were needed at the times specified for monitoring, the
monitoring was delayed until the procedure was completed and there had been time
for physiological parameters to return to normal. All monitoring was carried out by
one of three researchers (two research fellows and one research nurse).
The monitoring electrodes were positioned on the infant's chest or back, depending
on whether the baby was being nursed supine or prone. The position of the baby was
noted but was not altered for the purpose of the study since heart rate, rather than
ECG waveform data was required. Where possible, monitoring electrodes were
connected 5-10 minutes before monitoring was started, to avoid any changes in heart
rate induced by this process.
5.2.3 Extraction of Heart Rate Data
Data from the Holter monitor were collected prospectively, but the stored data from
the Badger system were viewed retrospectively. Wherever possible, data recorded on
Channel 1 was used. In some cases data on this channel was poor due usually to
movement artefact. In these circumstances, data from either Channel 2 or 3 was used,
after first examining to ensure that heart rate and heart rate variability from all three
channels were similar. For every period of monitoring using the DL700 Holter
monitor, the start and finish times were noted using the time displayed on the Badger
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system cot side computer corresponding to that baby. This was necessary to allow
later comparison of the data collected by the two different methods to be as accurate
as possible.
5.2.3.1 Calculation of mean heart rate and heart rate variability using
Holter monitor data
ECG data from each 15-minute period of monitoring was converted into text format
using the computer program referred to above. This returned a large amount of
numerical data (128 data points per second), corresponding to the recorded ECG
voltages for each sample in the format of a Microsoft Excel spreadsheet. Since it was
impractical to work with such a large amount of data, a 10 second period of data was
chosen and isolated. A random number generator [www.random.org] was used to
determine the start point between 300 and 600 seconds. By using the middle 5
minutes of the recording time, it was hoped that the data would represent a period at
which the infant was most likely to be at rest and there would be less likelihood of
interference due to vigorous movements of the baby. Each peak in voltage
representing the R wave of the ECG was identified and marked. A 20 beat period
was selected from this 10-second time span. The mean heart rate was calculated
across the 20 beats and the standard deviation about the mean heart rate was
calculated as a measure of heart rate variability over that time. A set number of beats
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were chosen rather than a given time period, because of the potential variation of
heart rate variability with changes in heart rate.
5.2.3.2 Calculation of mean heart rate and heart rate variability using
Badger System data
Types of patient monitors in use in the Neonatal Unit include Siemens and Hewlett
Packard monitors. All babies needing intensive care are monitored from the time of
admission to the Neonatal Unit using one of these. The type of monitor for any
individual baby depends only on the equipment available at the time of admission.
The Badger System extracts data from the patient monitor at a rate of once per
second. This one-second data produces a trend graph, which is constantly updated. A
computer program allows isolation of physiological data over any specified time
period during the baby's stay and calculation of the mean heart rate and heart rate
variability over that time. In this study, where babies had been monitored at regular
intervals for 15-minute periods using the Holter monitor, the same time period was
recalled on the Badger System (to an accuracy of within 1 minute). The mean heart
rate and standard deviation about the mean were calculated for the whole of that 15-
minute time span.
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5.2.4 Missing Data and Limitations of Data Collection Methods
5.2.4.1 Researcher availability
Data collection using the DL700 Holter monitor was limited to three researchers
only, in order to minimise the likelihood of inaccuracies. It was impossible for a
researcher to be present at all times when monitoring was required. This was due
mainly to the unpredictable nature of work involving newborn infants, unanticipated
clinical decisions affecting study drug administration or discontinuation and the high
intensity of work involved in obtaining 4 hourly data over a period of several days.
On most occasions, when monitoring took place between the hours of 06.00hrs and
02.00hrs, the required 15 minutes of data only was recorded. However, during the
night, and at other times when a research fellow was unable to be present, Holter
monitor recording was continuous for a number of hours to include the required 15-
minute time span. Start and finish times for continuous overnight monitoring were
sometimes less meticulously noted than were those for 15-minute periods. It is
therefore less easy to be certain, when extracting data collected over several 4-hour
periods, that times of data chosen from the two different methods will coincide
exactly and this may be a source of error when comparisons are made. Sometimes,
during prolonged periods of recording, Holter monitor battery failure meant that data
was not always complete. Another explanation for missing data in these
circumstances was removal of and failure to replace monitoring leads by medical or
nursing staff for clinical or other reasons.
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5.2.4.2 Clinical reasons
Although monitoring of babies begins on admission to the Neonatal Unit, data
recording by the Badger System depends on activation of the cot side computer,
following entry of the baby into the data management system. In very sick babies,
with many other clinical pressures, this may be delayed until clinical stability has
been achieved. In the extremely preterm who have particularly thin and fragile skin,
it is occasionally felt inappropriate to attach ECG leads. This means that in 6 infants,
initial data from the first few hours of life is unavailable, including baseline data
before administration of the study drug and during the loading dose.
During the course of intensive care, there will be other unavoidable gaps in
monitoring. ECG electrodes must always be removed for chest x-rays to be carried
out, shorter periods of data are lost when electrodes are routinely replaced and in
some instances the condition of a baby's skin may make invasive arterial monitoring
preferable.
As the condition of an infant improves, less monitoring is clinically required and so
Badger System monitoring is discontinued. For this reason, more data are available
from intermittent Holter monitoring towards the end of the study period for all but
the sickest babies who require a very prolonged period of intensive care. Data
collection is also discontinued early in babies transferred to other hospitals for their
ongoing care. Similarly, in babies for whom survival is unlikely, data is limited due
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to elective discontinuation of routine clinical monitoring during compassionate care
and the inappropriateness of continuing research in such babies.
5.2.4.3 Artefact
Corruption of data by artefact is seen when there is failure of, or interference with,
detection or transmission of physiological data signals, adversely affecting the
quality of the recording obtained. A common cause of artefact in ECG recording is
poor contact between the electrode and skin, seen in babies who are very active.
Accidental movement of the electrodes during routine care is also common, and
accounts for brief periods of data that are difficult or impossible to interpret
meaningfully. The problem of data artefact applies to both methods ofmonitoring. It
is usually possible to identify artefact by carefully examining the ECG trace.
Fallacious physiological changes due to artefact are usually abrupt, immediate and of
large magnitude. The values may return to normal equally rapidly. This is in contrast
to true physiological change in heart rate that tends to be more gradual both in onset
and recovery. However, genuine profound changes may occur that bear some
resemblance to artefact such as bradycardia accompanying endotracheal suction in
unstable infants.
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No systematic method for artefact detection or removal was available for data
obtained in this study. However, since the study aimed to examine mean heart rate
and heart rate variability in a small block of data representative of a longer time span,
it was necessary to avoid periods of recording where artefact was obvious or
suspected. When viewing the randomly chosen data from the Holter monitor
recording, a line graph of the data including the R wave markers was plotted using
Microsoft Excel and examined to ensure that the 20-beat trace appeared regular with
no artefact included (Figure 5.1). If this was unsatisfactory, a further randomly
selected 20-beat period was examined and utilised. All Badger data was examined
for recognisable patterns indicating artefact or sudden change in physiological
parameters. If either was seen, an alternative 15-minute period within 45 minutes of
the chosen time was used. Extremely brief interruptions in monitoring, where there
was clearly no deviation of the trace from baseline, were ignored. With both methods
of monitoring, if no satisfactory portion of ECG trace could be identified around the
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5.3.1 Comparison of methods of ECG monitoring
36 infants were monitored using the Badger System. 29 infants had some monitoring
using the Braemar DL700 holter monitor. Parallel data from both the Holter monitor
and Badger system are available for 29 infants.
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Figure 5.2
Holter monitor data: Mean HRV v Mean HR
Linear Regression



























































Plots of all heart rate data showing mean heart rate against heart rate variability for
both groups show that in the case of Holter monitor recordings, increasing mean
heart rate is accompanied by a small decrease in heart rate variability (Figure 5.2), in
keeping with findings of other researchers.14 This is not seen in the Badger System
group (Figure 5.3) where there are a larger number of measurements available and
calculations are made over a greater period of time. The spread of results is greater
for both mean heart rate and heart rate variability when measured using the Badger
System. The variability is generally higher in this group than the Holter monitor
group. This is not an unexpected finding; it would be expected that measurements
using the Holter monitor would be more precise, since variability in rate from one
beat to another is measured over an extremely brief time period. In contrast, the
Badger System uses averaged data, collected over a longer time. This small
difference in absolute figures is unlikely to present a problem clinically if it is
consistent.
In order further to compare the two different means of data collection and to estimate
the level of agreement between them, Bland-Altman plots were used (Figures 5.4 and
5.5). In these plots, the differences between the two results for mean heart rate and
the heart rate variability are plotted against the means of the measures. The parallel
horizontal lines represent the 95% confidence limits for agreement. Figure 5.5
demonstrates that the difference between the two methods in the measurement of
variability increases as the heart rate variability itself rises. However, for both mean
heart rate and heart rate variability, most points (93% and 94% respectively) fall
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within the 95% confidence limits, indicating that agreement between the two
methods is acceptable.
Since there was a good level of agreement between the two methods of heart rate
monitoring, further analyses of mean heart rate and heart rate variability data were
carried out on data obtained from the Badger System.
Figure 5.4
Mean HR Badger-Holter v Mean
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36 infants enrolled in the N.E.O.P.A.I.N. Study were monitored using the Badger
System. Of these, 18 infants were randomly allocated to receive morphine infusion
and 18 were allocated to receive placebo. Table 5.1 shows that there were no
significant differences between the two groups in gender, gestational age, birth
weight, severity of illness measured by the CRIB Score (Clinical Risk Index for
Babies) 136 and number of days on study infusion. Table 5.2 show the numbers of
infants remaining in the study and able to be studied at each point in time. Part A
shows the numbers of babies receiving maintenance infusion from the time of
starting the study drug until 14 days. Part B includes only those babies who received
the study drug for more than 48 hours and therefore required a period of up to 48
hours' weaning. Part C shows the number of babies in each group who were studied
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following discontinuation of the study infusion. This includes infants whose infusion
had been weaned and those who had not required weaning.
To ascertain whether the commencement of morphine infusion led to a change in
mean heart rate or heart rate variability, it was necessary to compare the changes
from baseline in every baby. Baseline data for 6 babies were unavailable. In view of
the already small numbers in the study, imputation of data would be difficult and
could lead to erroneous results. These 6 infants were therefore excluded from the
analysis of both mean heart rate and heart rate variability
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Table 5.1: Characteristics of infants studied
Morphine Placebo Significance*
No. of babies 18 18
Male / female 10/8 8/10






































*Mann Whitney U; Values are expressed as median (range)
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Day 1 13 18
Day 2 16 16
Day 3 14 8
Day 4 11 8
Day 5 3 8
Day 6 2 7
Day 7 1 6
Day 8 1 6
Day 9 1 6
Day 10 0 6
Day 11 0 6
Day 12 0 5
Day 13 0 5
Day 14 0 3
B
Wean 4 hours 8 6
Wean 8 hours 8 6
Wean 12 hours 7 6
Wean 16 hours 6 6
Wean 20 hours 5 6
Wean 24 hours 5 6
Wean 28 hours 3 5
Wean 32 hours 3 5
Wean 36 hours 3 5
Wean 40 hours 3 5
Wean 44 hours 1 5
Wean 48 hours 1 5
c
Stop 4 hours 14 11
Stop 8 hours 14 11
Stop 12 hours 14 11
Stop 16 hours 13 10
Stop 20 hours 13 10
Stop 24 hours 14 12
Stop 28 hours 14 12
Stop 32 hours 14 12
Stop 36 hours 14 12
Stop 40 hours 14 12
Stop 44 hours 14 12
Stop 48 hours 13 12
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Figure5.6
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5.3.2 Comparison of mean heart rate and heart rate variability in babies
receiving morphine and placebo
Figures 5.8 and 5.9 show the values for mean heart rate and heart rate variability over
the first 4 days of administration of the study infusion. To avoid problems associated
with multiple T testing 137 and unequal numbers of subjects within different groups,
comparisons of change in mean heart rate and heart rate variability were made using
analysis of covariance.
Figure 5.8
Mean heart rate before study infusion





















N = 14 16 13 16 14 14 11 7
BaselineL Day 1 Day 2 Day 3
Time (days)


























Heart rate variability before study infusion
and on days 1-4 of maintenance infusion
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□ Placebo
Figure 5.10 shows a plot of mean heart rate on days 1 and 2 of maintenance study
infusion with baseline mean heart rate. Analysis of covariance indicates a statistically
significant difference in the measurements between the morphine and placebo groups
(p = 0.024) with the heart rate in babies treated with morphine falling with the onset
of treatment more than in the placebo group. Figure 5.11 shows a similar plot for
heart rate variability. Again, the level of variability during the first 48 hours of
morphine therapy is reduced compared with that in the placebo group (p = 0.065).
Although this result does not reach statistical significance, a trend is seen in this
group of infants.
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By days 3 and 4 of treatment with the maintenance infusion, this difference between
the two study groups is no longer evident. Figures 5.12 and 5.13 show plots of day 3
and 4 results with baseline values of mean heart rate and heart rate variability
respectively. Indeed, Figure 5.7 shows an increase in heart rate variability in the
morphine group as compared to the placebo group after day 4. Using analysis of
covariance to compare the two groups, there is no difference between baseline values
and those obtained on days 3 and 4 for mean heart rate (p = 0.521) and heart rate
variability (p = 0.804).
Figure 5.10
Plot of mean heart rate on days
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Figure 5.11
Plot of heart rate variability on days
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Figure 5.12
Plot of heart rate variability on days
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Plot of heart rate variability on days
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5.3.3 Comparison of mean heart rate and heart rate variability in babies
after discontinuation of morphine or placebo
Figures 5.14 and 5.15 show available data for mean heart rate and heart rate
variability in babies after discontinuation of morphine or placebo infusion. These
results include values from the whole group of babies randomised into the study;
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regardless of the length of time the infants received the study drug. The infusion will
have been discontinued abruptly without a weaning period in those babies who
received the infusion for 48 hours or less. In all babies who received the study drug
for more than 48 hours, there will have been a weaning period of up to 48 hours.
Figure 5.14
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Figure 5.15
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Analysis of variance would be the most appropriate method for analysis of the data
showing the changes over time after stopping the study infusion. However, given the
unequal numbers in the groups, the data are unsuitable. Likewise, multiple T testing
is known to lead to erroneous results. The data were therefore analysed by
calculating the slope of the line for each group and comparing these slopes using the
independent samples T test137.
There is no significant difference between the two groups of infants for either mean
heart rate (p = 0.616) or heart rate variability (p = 0.080) during the first 48 hours
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after stopping the study infusion. However it is interesting to note that the group of
babies receiving morphine show relative tachycardia in comparison with the placebo
group. This is a change from the time on maintenance infusion, where the mean heart
rate in the morphine group was reduced compared with controls. Heart rate
variability remains relatively reduced in the morphine group until around 20 hours of
age. Thereafter, the values become similar again in the two groups toward the end of
the 48-hour period.
5.3.4 The effect of weaning
Figures 5.16 and 5.17 show results after discontinuation in the infants in whom there
was no weaning of the study infusion. There is a suggestion of higher mean heart
rates within the morphine group in this plot continuing through the period after
discontinuation of therapy. After discontinuation of the study drug, when the effect
of weaning is included as an interaction in the analysis, there is no statistical
difference between slopes for either the mean heart rates (p = 0.544) or the heart rate
variability (p = 0.615) in the morphine and placebo groups. Weaning therefore does
not appear to influence either variable.
Figures 5.18 and 5.19 show the mean heart rate and heart rate variability for the two
groups during the period of weaning. The reduced mean heart rate seen in the
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morphine group on maintenance infusion appears to persist into the weaning period
although the difference in slopes does not reach statistical significance (p = 0.117).
There is no significant difference in slopes for heart rate variability between the two
groups (p = 0.123).
Figure 5.16
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Figure 5.17

























54 54 54 54 44 54 54 54 54 54 54 54
4 8 12 S16 20 24 28 32 36 40 44 48
Time (hours)
Error bars represent mean +/- SE
Figure 5.18
























565 56 46 36362525 25 25 5 5
4 8 12 16 20 24 28 32 36 40 44 48
Time (hours)



























65 65 56 46 36 36 25 25 25 25
4 8 12 16 20 24 28 32 36 40
Time (hours)
Error bars represent mean +/- SE
5.3.5 The Effect of Gestational Age
For the purpose of data analysis, the infants are divided into the gestational age and
morphine dosage groups that were chosen for stratification in the NEOPAIN
Multicentre Trial. Therefore, in the following section, groups are analysed as
follows:
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1. Infants of 23-26 weeks' gestation who received lOmcg/kg/hour of
morphine or equivalent volume of placebo (n = 16)
2. Infants of 27-29 weeks' gestation who received 20mcg/kg/hour of
morphine or equivalent volume of placebo (n = 14)
3. Infants of 30-32 weeks' gestation who received 30 mcg/kg/hour of
morphine or equivalent volume ofplacebo (n = 6)
5.3.5.1 Group 1
Figures 5.20 and 5.21 show the mean heart rate and heart rate variability in babies of
23-26 weeks' gestation during the first four days of the study. Figures 5.22 and 5.23
show plots of day 1 and 2 results with baseline results for both groups. Using
analysis of covariance, the difference between the two groups on starting morphine
trends towards statistical significance in this subgroup of infants (p = 0.084). There is
no significant difference in heart rate variability with the onset of treatment (p =
0.399).
As with the whole study group any difference in mean heart rate from baseline
disappears by day 3-4 (figures 5.24 and 5.25) of the study infusion in this subgroup
(p = 0.873). No significant difference in heart rate variability is seen (p = 0.814).
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Figure 5.20
Mean heart rate before study infusion and on
days 1-4 of maintenance infusion
(23-26 weeks)
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Plot of mean heart rate on days
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Plot of heart rate variability on days











Plot of mean heart rate on days 3-4
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Figure 5.25
Plot of heart rate variability on days 3-4
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Mean heart rate and heart rate variability in all infants born at 23-26 weeks' gestation
for the period after discontinuing the study drug are shown in Figures 5.26 and 5.27.
Comparison of the slopes for both groups shows that there is no significant
difference between them over the period of 48 hours after stopping the infusion for
either mean heart rate (p= 0.528) or heart rate variability (p = 0.828). This analysis
includes all babies whether or not the study drug was weaned before discontinuation.
Weaning does not influence either mean heart rate (p = 0.914) or variability (p =
0.835)
Figures 5.28 and 5.29 show mean heart rate and heart rate variability data for those
babies in the 23-26 week gestational group for whom the study infusion was weaned.
There is no significant difference in slopes between the two groups for either mean
heart rate (p = 0.304) or variability (p = 0.508)
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Figure 5.26
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Figure 5.29
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Figures 5.30 and 5.31 show the mean heart rate and heart rate variability in babies of
27-29 weeks' gestation during the first four days that they received the study
infusion. Figure 5.32 and 5.33 show plots of day 1 and 2 mean heart rate and heart
rate variability with baseline values. Using analysis of covariance, the difference
between the two groups on administration of the study infusion does not reach
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Figure 5.33
Plot of heart rate variability on days






Baseline heart rate variability (beats/minute)
Figure 5.34
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Figure 5.35
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Figure 5.34 shows the mean heart rate during the 48-hour period immediately after
stopping the study infusion. There is no significant difference between the morphine
and placebo groups in terms of the change in heart rate over this time (p = 0.918).
However there is clearly a relative tachycardia in the morphine group compared with
the placebo group. There is no difference between the groups in heart rate variability
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Figure 5.37
































11 11 1 12 121211111111 1 1







Error bars represent mean +/- SE
83
5.3.5.3 Group 3
The number ofbabies included in the study of 30 weeks gestation or more is
extremely small. This means that no further analysis of these babies can be
performed.
5.4 DISCUSSION
This study examined the differences in mean heart rate and heart rate variability
between groups of preterm ventilated infants randomised to receive either morphine
for analgesia, or placebo.
The analysis of the data is limited due to the repeated measures, small and unequal
numbers within the groups and the amount of missing data. Analysis of covariance
was used to examine the difference between baseline values and those obtained
during the course of the infusion. Comparison of slopes was used to examine for any
difference between the two groups over time for the period of weaning and the
period of observation after stopping the study drug. This method of data analysis
avoids the difficulties associated with multiple testing, and will show large and
consistent differences between groups over time. However, it might fail to highlight
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subtle trends in the data that might be present. Although numbers in this study are
small, there are some significant results, identifiable trends and observations, which
warrant further discussion.
If morphine were effective as an analgesic in this situation, a response would be
expected soon after administration of the loading dose. A relative decrease in mean
heart rate would be anticipated compared with infants receiving placebo. Heart rate
variability is more complex and the expected changes are less easy to define.
Although reduced variability has been observed in sick ventilated preterm newborns
13'14, increased variability has also been seen in response to handling and procedural
pain and it has been considered as a measure of physiological instability. Previous
138 .....work has demonstrated a reduction in heart rate variability with morphine
infusion. After discontinuation of the study drug, it would be expected that these
parameters would become similar again within the two groups.
The heart rate is similar in the two groups before the study infusion is commenced.
On initiation of treatment with morphine, there is an appreciable fall in mean heart
rate compared with the placebo group that reaches statistical significance. This
response may be an indication that morphine is effective in reducing pain and stress
in this situation. Heart rate variability is similarly, though not significantly reduced in
the morphine group, in keeping with previous work in this area138. This lends support
to the hypothesis that increased heart rate variability indicates pain or stress that can
be reduced by the use of analgesia. The change in mean heart rate from baseline does
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not reach statistical significance on analysis of subgroups according to gestational
age. However, results for the 23-26 week group show a trend towards significance.
This might indicate that the more preterm infants, as well as being more sensitive to
pain 18;1395 have a greater response to analgesia than those of greater gestational age.
The disappearance of the difference between the groups on days 3 and 4 of the
infusion raises the possibility of development of tolerance to the medication.
Unfortunately the numbers of infants receiving the study drug for a prolonged time
are too few to allow meaningful interpretation of later results.
The data were also analysed for indication of opiate withdrawal. This would be
expected to be more likely to occur in infants who have received morphine for a
prolonged period of time. However, the protocol for the NEOPAIN study required
the study infusion to be weaned in these infants in order to avoid any potential
adverse events on discontinuation. In this group, therefore, it would be expected that
the weaning would attenuate any withdrawal effect seen. It is not thought that
withdrawal phenomena are likely to occur following short-term opiate
administration.
When the groups of babies are analysed as a whole, without taking into account any
effect of weaning, there is no difference between the groups over time after stopping
the study infusion. However, the infants whose mean heart rates were suppressed by
morphine during the maintenance period are now relatively tachycardic when
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compared with the infants receiving placebo. This possible rebound effect is even
more marked in the 27-29 week infants (Figure 5.34), but is not seen in the 23-26
week group. This indicates a possible sign ofwithdrawal. The difference in response
between the gestational age groups is interesting. In the older group, who received
morphine 20mcg/kg/hour, the change in heart rate might indicate the increased effect
of discontinuing a higher dose of the opiate in comparison with the 1 Omcg/kg/hour in
the lower age group. Another possible explanation is that the infants of the lowest
gestation group are not sufficiently mature to be able to alter heart rate variability in
the same way as older infants. This group is also more likely to be more unwell. The
lack of change in variability might therefore be a reflection of ongoing severity of
illness exerting a greater effect than the withdrawal of medication. Although scores
such as the CRIB score give an indication of severity of illness as measured within
the first hours of life, no scoring system has been developed and validated for use
during the subsequent course of neonatal intensive care.
Figure 5.15 shows persisting decreased variability in the morphine group for the first
16 hours of weaning, with the two groups becoming similar towards the end of the
48-hour period of weaning. This might also indicate an opiate withdrawal response.
It is unfortunate that the low numbers of babies in the individual gestational age
groups, and particularly in the 30-32 week group prevents analysis of this group.
Those infants who received the study infusion for more than 48 hours will fall into
the weaning group. When the results from these infants are looked at separately, a
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marked reduction in mean heart rate in the morphine group is clearly seen for the
whole duration of the infusion. This holds true in the 23-26 week infants, but is not
seen in the more mature group where numbers are too small to allow any inference to
be made.
Infants who only received the study infusion for 48 hours or less did not have the
drug weaned. They show a similar rebound increase in mean heart rate on stopping
the infusion that persists until 32 hours after the drug has been discontinued.
Thereafter, the two groups have similar mean heart rate. This raises the possibility of
a withdrawal effect even after short periods of therapeutic opiate administration,
though this has previously been thought unlikely. This change occurs at a time when,
clinically, infants are sometimes reported by nursing staff as being more "active" or
"agitated". The heart rate variability of these babies remains depressed for the first
hours after discontinuation of the drug, but by 24 hours after, the variability of the
two groups has become similar. This is in keeping with the pattern that would be
expected, assuming that there is no withdrawal effect.
The numbers of babies studied are very small. The results must therefore be
interpreted with great caution and no conclusions can be drawn from this work.
There are, however, a number of factors as discussed above that bear consideration in
future work on the subject of pain and analgesia in the newborn.
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5.5 SUMMARY
Mean heart rate and heart rate variability were studied in 36 preterm ventilated
newborn infants randomised to receive morphine or placebo infusion. There is
evidence that morphine is effective in decreasing pain and /or stress associated with
ventilation, shown by a decrease in mean heart rate and variability on starting the
drug. The results also suggest possible development of tolerance after three or four
days of treatment with a loss of these effects. Rebound tachycardia and increase in
heart rate variability on weaning and discontinuation of the infusion support the
hypothesis that there may be a recognisable phenomenon of opiate withdrawal
associated with discontinuation of therapeutic doses of morphine. This is more
obvious in infants who have received higher doses ofmorphine.
None of the results obtained in this small study reach statistical significance. Further
investigation in a larger group of babies is necessary to confirm these findings.
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CHAPTER 6
EFFECTS OF ANALGESIA ON THE CUTANEOUS
FLEXOR WITHDRAWAL REFLEX IN PRETERM
VENTILATED INFANTS
6.1 BACKGROUND
The cutaneous flexor withdrawal reflex or nociceptive flexion reflex is thought to be
a polysynaptic reflex140. When a noxious stimulus is applied to the sole of the foot,
pain receptors are stimulated and the resulting nerve impulse is conducted via
unmyelinated C fibres and thinly myelinated A-delta fibres to the spinal cord dorsal
horn141. This results in ipsilateral flexion at the ankle, knee and hip resulting in
withdrawal from the stimulus. Studies in adults suggest that there is a linear
correlation between the threshold for the cutaneous flexor withdrawal reflex and the
subjective perception of pain142. The threshold for the maximal reflex response is
similar to that for intolerable pain and the threshold is increased by the
administration of analgesics143. The cutaneous flexor withdrawal reflex has been
used in newborn infants to investigate and quantify response to pain19. Studies have
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shown that flexion reflex thresholds in the newborn are much lower than those in
adults and gradually increase with postnatal age18. Repeated stimulation of the skin
in premature infants causes sensitisation and the flexor reflex can be induced by non-
noxious as well as noxious stimuli.
In neonates, the flexor reflex threshold has been elicited using von Frey hairs.
Although the cutaneous withdrawal reflex is associated with the anatomical
structures related to perception of pain, stimulation using von Frey hairs to induce
this reflex does not appear to be perceived as a painful stimulus and it can be induced
by both noxious and tactile stimuli. In the adult, the threshold of the reflex has been
shown to be useful as a measure of spinal cord excitability and is reduced with
exposure to nociceptive stimuli. In the newborn infant it also appears to be useful as
a measure of this excitability19 Inhibition of the reflex has also been shown to occur
with stimulation of the contralateral limb suggesting that even in preterm babies,
nervous connections are functional. Although the withdrawal reflex cannot be
regarded as a direct measure of pain, it can be a useful guide to the somatosensory
state of infants undergoing intensive care.
Each von Frey hair is a single nylon filament, attached at right angles to a perspex
handle. The set of von Frey hairs used in this work consists of 20 numbered hairs of
different thickness, ranging from very fine (Number 1) to very thick (Number 20).
The tip of the nylon filament is placed onto the skin of the subject and downward
pressure is exerted in the direction of the hair until the hair bends. The weight
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required to bend the hair is different for each one and it is quantifiable and
reproducible. Hairs of increasing weight are applied to the foot in this way until the
cutaneous flexor withdrawal reflex is seen. This point is the threshold of the reflex.
The reflex has been used extensively in pain research, but its potential for clinical
application has not been assessed. This study investigates the change in the flexor
withdrawal reflex threshold associated with administration of analgesia and
withdrawal of therapeutic doses of analgesia in preterm newborn infants. The
potential of the reflex as a method of assessing adequacy of analgesia and evaluating
protocols for weaning of opiate analgesia is explored.
6.2 METHODS
6.2.1 Equipment
Two sets of von Frey hairs were used for the measurement of the cutaneous flexor
withdrawal reflex. Each set consisted of 20 hairs as described above. In the group of
neonates assessed, all thresholds were elicited with hair numbers 6-17. Hair
numbers and the corresponding weights required to bend the hairs are shown in
Table 6.1. The same set of hairs was used for all measurements on any individual
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baby. The von Frey hairs were stored in the intensive care nursery of the Neonatal
Unit for the duration of the study.
Table 6.1














Assessment of the threshold of the cutaneous withdrawal reflex was performed on 33
of the babies recruited to the NEOPAIN study. Babies were tested at the following
times:
I. Prior to administration of the study drug
II. Daily for the duration of the maintenance dose of the study drug
III. Every 4 hours during the period ofweaning of the study drug for up to 48 hours
IV. Every 4 hours after discontinuation of the study drug
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On most occasions, testing followed the 15-minute period of ECG monitoring so that
the baby had not been disturbed during that time. Where ECG monitoring was not
carried out, testing followed a period of at least 15 minutes undisturbed rest. In the
less stable babies, this was not always possible due to frequent nursing or medical
procedures. Where essential nursing or medical procedures were needed at the time
when testing should have taken place, it was delayed until the procedure was
completed and there had been time for the baby to return to a state of rest.
The position of the baby was noted but was not altered for the purpose of the study.
During the first days of life, when infants are unstable and require invasive blood
pressure monitoring using umbilical catheters, babies are usually nursed in supine or
lateral positions. Thereafter, position is altered at regular intervals and the babies
spend some of their time prone. The behavioural state of the infant was also noted.
At the time of testing, babies were quietly awake or asleep; babies who were crying,
restless or in a very active state were not tested.
The foot was exposed and the infant was tested using von Frey hairs to assess the
threshold for reflex withdrawal. Starting with von Frey hair number 6, the stimulus
was applied to the lateral plantar surface of the foot. This was repeated using
increasingly heavy graded hairs until the threshold was established. The threshold
response was defined as clear withdrawal of the leg from the stimulus, involving
flexion at the knee and hip, as well as movement at the ankle or foot. The number of
the hair used to elicit this response was recorded.
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6.2.2 Missing Data and Limitations of Data Collection Methods
6.2.2.1 Researcher availability
In order to minimise inaccuracies and interobserver error, most measurements were
made by a single observer. However, it was impossible for any one person to be
present at all times when testing was required. This was due mainly to the
unpredictable nature of work involving newborn infants, unanticipated clinical
decisions affecting study drug administration or discontinuation and the high
intensity of work involved in obtaining 4 hourly data over a period of several days.
This resulted in an unacceptably large amount of missing data for some babies.
Therefore, two other researchers were instructed on the use of von Frey hairs. Since
it is known that with repeated stimulation, a baby's response will change as
1 8
hypersensitivity develops , it was not possible to test agreement between observers
for any single measurement in a baby. The measurements of the additional
researchers were observed to ensure that all observers agreed on the point at which
the reflex was elicited.
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6.2.2.2 Clinical reasons
In very sick babies, during the first few hours of life, after admission to the Neonatal
Unit, many procedures are undertaken to achieve clinical stability and adequate
monitoring. These include venous cannulation and insertion of umbilical arterial and
venous catheters. Such procedures are carried out aseptically and require the baby to
be covered with sterile drapes. In these circumstances, it was impossible to expose
the foot to test the threshold. In some cases, the testing was delayed, but in others,
data for that time period is unavailable. This also applies at times later in the course
of intensive care when similar procedures are necessary.
Extremely premature babies have fragile blood vessels and the need for vascular
access for administration of fluids and drugs and for invasive monitoring often
presents difficulties. Resiting of venous and arterial cannulae is a frequent
occurrence. The feet are common areas for these to be sited, meaning that sometimes
neither foot is accessible due to the presence of cannulae, and securing tape or
splints.
Data collection is discontinued early in babies transferred to other hospitals for their
ongoing care. Similarly, in those babies for whom the prognosis is extremely poor,
data is limited due to reorientation to compassionate care and the inappropriateness
of continuing research in such babies.
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6.2.2.3 Technical Limitations
The von Frey hairs used in this study were calibrated at the time of manufacture.
Over time, it is possible that changes in the material may have occurred, which mean
that the weight required to deform each hair may not be exactly the same as it was at
the time of manufacture. Attempts were made to check this. Each hair was applied to
a finely calibrated balance and the weight at which the hair bent was recorded.
However, this was unsuccessful due to the inability to apply downward pressure in
the direction of the hair without the hair tip moving across the smooth surface of the
balance. More accurate and sophisticated equipment has recently been developed for
applying differing pressures with a single electronic device, but such equipment was
unavailable to us for this study.
6.3 RESULTS
Assessment of the cutaneous flexor withdrawal reflex was performed on 33 of the
babies recruited to the NEOPAIN Study. Of these, 19 babies received morphine
infusion and 14 were assigned to placebo. Table 6.2 shows that the study groups do
not differ significantly at baseline in terms of birth weight, gestational age, number
97
of days on study infusion, severity of illness as defined by the CRIB score or
threshold for the cutaneous flexor withdrawal reflex.
A scatter plot showing the baseline reflex withdrawal threshold for all babies
confirms the relationship between the threshold and gestation (Figure 6.1). Babies
were tested during the first few hours of life, so these values represent the threshold
prior to commencement of the study infusion
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Table 6.2: Characteristics of babies studied
Morphine Placebo Significance*
No. of babies 19 14
Male / female 11/8 7/7






































*Mann Whitney U; values are expressed as median (range)
99
Figure 6.1





























22 24 26 28 30
Gestation (weeks)
'Sunflowers' show overlying points. Each 'petal' represents 1 case
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6.3.1 Comparison of flexor reflex threshold sensitivity in babies
receiving morphine and placebo
Table 6.3 parts A, B and C and Figure 6.2 show the babies for whom results are
available. The cutaneous flexor withdrawal reflex thresholds for babies in each of the
two study groups before starting the study infusion, during the maintenance infusion
and weaning periods of the study, and for the first 48 hours after discontinuation of
the study infusion are shown. Most infants discontinued or began weaning the study
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infusion for clinical reasons after only four days. Others have very few results after
this time for the reasons highlighted earlier. Meaningful interpretation of the small
number of results obtained after day 4 of maintenance study infusion would be
impossible; therefore only results for days 1 - 4 are considered in the analysis of
babies during the time on maintenance infusion.
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Table 6.3: No. days treatment with study drug
A
Sample Morphine Placebo
(no. infants) (no. infants)
Baseline 19 14
Day 1 12 10
Day 2 14 11
Day 3 10 4
Day 4 3 4
Day 5 1 3
Day 6 0 1
Day 7 0 1
Day 8 1 2
Day 9 1 1
Day 10 0 0
Day 11 0 0
Day 12 0 1
Day 13 0 2
Day 14 0 1
B
Wean 4 hours 5 6
Wean 8 hours 5 4
Wean 12 hours 4 3
Wean 16 hours 3 3
Wean 20 hours 3 3
Wean 24 hours 3 3
Wean 28 hours 1 3
Wean 32 hours 1 4
Wean 36 hours 2 2
Wean 40 hours 1 3
Wean 44 hours 1 4
Wean 48 hours 1 2
C
Stop 4 hours 8 8
Stop 8 hours 8 7
Stop 12 hours 8 8
Stop 16 hours 2 2
Stop 20 hours 5 4
Stop 24 hours 6 5
Stop 28 hours 3 5
Stop 32 hours 2 4
Stop 36 hours 2 4
Stop 40 hours 0 1
Stop 44 hours 1 2
Stop 48 hours 1 4
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Figure 6.3
Threshold sensitivity before study infusion
and on days 1-4 of maintenance infusion
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Figure 6.3 shows the threshold sensitivity for the cutaneous flexor withdrawal reflex
before administration of the study infusion and during the first 4 days on
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maintenance infusion. To avoid problems associated with multiple T testing and
unequal numbers of subjects within different groups, comparisons of change in the
cutaneous flexor withdrawal reflex threshold were made using analysis of
covariance. Figure 6.4 shows a plot of mean threshold on days 1 and 2 of
maintenance study infusion with baseline threshold. Comparing the morphine and
placebo groups, there is no difference in the change from baseline values to those on
days 1 and 2 (p = 0.668).
6.3.2 Comparison of flexor reflex threshold sensitivity in babies after
discontinuation of morphine or placebo
Figure 6.5 shows the reflex threshold sensitivities after discontinuation of the study
infusion. Results for all babies are included in this chart, whether or not there has
been a period of weaning before stopping the infusion. These data were analysed
using comparison of the slopes between the groups. There is no significant difference
in the threshold between the morphine and placebo groups during the first 48 hours
after discontinuing the study drug (p = 0.847)
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Figure 6.5
Threshold sensitivity after stopping study
infusion (all babies)
N = 88 878822 54 653524 24 1 12 14
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Error bars represent mean +/- SE
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6.3.3 The effect of weaning
Figure 6.6 shows the threshold for reflex withdrawal in the group of infants where
there has been no weaning of the study drug. When the effect of weaning is
considered in the analysis, there is still no significant difference between the two
study groups after stopping the infusion (p = 0.637).
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In the group of babies where weaning was necessary, there is a significant difference
between the groups when comparison is made between the slopes of the groups (p =
0.029). Higher numbers of von Frey hair indicate decreased sensitivity to the
stimulus. Figure 6.7 shows that from the time of initiation of weaning and for the
next 20 hours, the threshold in the morphine group is generally higher than that in the
babies receiving placebo. Thereafter, until discontinuation of the study drug, the
infants receiving morphine therapy show increased sensitivity to the von Frey hair
stimulus compared with the infants receiving placebo infusion.
Figure 6.6
Threshold sensitivity after stopping study
infusion (no weaning)
N = 64 44 54 2 2 5434 2323 1 12 13
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Threshold sensitivity during weaning of study
infusion
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Error bars represent mean +/- SE
6.3.4 The Effect of Gestational Age
The small numbers of babies included in this study and the fact that no difference has
been shown between the two treatment groups overall means that no meaningful
subgroup analysis can be performed.
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6.4 DISCUSSION
The threshold for the cutaneous flexor withdrawal reflex is thought to correlate well
with pain threshold. In this study, it is used as a measure of pain threshold. The
differences between the threshold in preterm infants randomised to receive morphine
or placebo are explored.
The analysis of the data is limited due to the repeated measures, unequal numbers
within the groups and the amount of missing data. Analysis of covariance was used
to examine the difference between baseline values and those obtained during the
course of the infusion. Comparison of slopes was used to determine any difference
between the two groups over time for the period of weaning and observation after
discontinuation of the study drug.
Initially, this study confirms the relationship described by Fitzgerald et al18 between
increasing gestational age and increasing reflex threshold. Since, in this study, almost
all babies have discontinued the study infusion by the end of the first week of
maintenance dose, the change with age is unlikely to affect the results.
If preterm infants experience pain in association with mechanical ventilation and
morphine is effective as an analgesic, then it would be expected that the threshold for
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the cutaneous flexor withdrawal reflex would be increased in ventilated infants
receiving morphine compared with those receiving placebo infusion. On
discontinuing the study infusion, this difference would be expected to disappear.
In this study, no significant difference compared with baseline values is seen in
either mean heart rate or heart rate variability on administration of the study infusion.
One possible explanation for this result is that the morphine dose was not adequate
for pain relief. Although data on pharmacokinetics of morphine in the preterm
neonate are few and suggest that there is great variability144'145, previous studies have
found morphine levels to be adequate with doses of 10 - 30mcg/kg/hour. Morphine
has been shown to considerably reduce catecholamine levels in preterm ventilated
infants64'146. Contributing factors to stress in sick newborn infants are many, and
almost certainly include pain. It is possible, however, that the dose of morphine
needed to produce a reduction in stress hormones may not be enough to alter the pain
threshold in these infants. No indicator has been identified that is specific for pain.
The most reliable indicators known are behavioural and these are less relevant in the
situation of chronic pain than acute pain; high levels of stress hormones are not
necessarily associated with behavioural indicators of pain64.
No difference is shown between the morphine and placebo groups after
discontinuation of the study infusion where the effect of weaning is not considered.
In infants where weaning from the infusion was not required, the groups are similar
throughout. The significant difference between groups over time during the weaning
period might suggest the development of increased sensitivity after 20 hours of
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weaning. The very small numbers, however, do not allow such conclusions to be
drawn.
6.5 SUMMARY
The cutaneous flexor withdrawal reflex was explored in 33 preterm ventilated
newborn infants randomised to receive morphine or placebo. There was no
significant difference in the reflex threshold between the groups on starting
treatment, during weaning of the infusion or after discontinuation of the drug. Small
numbers, particularly later in the study mean that this work would be very unlikely to
identify any differences present.
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CHAPTER 7
EFFECTS OF ANALGESIA ON MEAN HEART RATE
AND HEART RATE VARIABILITY IN INFANTS
UNDERGOING OPHTHALMOLOGICAL EXAMINATION
7.1 BACKGROUND
7.1.1 Screening for Retinopathy of Prematurity
Retinopathy of prematurity is a condition exclusively affecting preterm babies. The
incidence of disease has increased with the increasing survival of very low birth
weight infants. It is a disorder in which there is interruption of the normal
development of vasculature of the retina and it is characterised by formation of new
and abnormal retinal blood vessels. The condition often resolves spontaneously over
time, but can progress to severe disease with scarring, retinal detachment and visual
impairment. It is a leading cause ofblindness in infants born prematurely147.
In infants whose disease shows progression to a level requiring treatment (threshold
disease), laser therapy is effective in preventing further progression if initiated at this
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stage148. Guidelines for screening have therefore been drawn up by a Joint Working
Party of The Royal College of Ophthalmologists and the British Association of
Perinatal Medicine149. In accordance with these recommendations, all infants at the
Royal Infirmary of Edinburgh born at gestations below 32 weeks or with birth weight
of less than 1500g receive ophthalmological examination on the Neonatal Unit.
Screening begins at 6 weeks postnatal age, or 36 weeks corrected gestational age,
whichever is earlier. Screening examinations are performed at regular intervals until
the retina is fully vascularised. This aims to detect and monitor the disease in its
early stages to allow for appropriate intervention.
7.1.2 Behavioural responses to eye examination
Examination of each eye for retinopathy of prematurity involves retraction of the
eyelids using a lid speculum and manipulation of the eye using a muscle hook.
Indentation of the eye often occurs during the examination. Such procedures have
been reported to be painful by adults. When the eye examination begins and during
the course of the procedure, infants display responses that are recognised indicators
of acute pain in preverbal infants - brow bulge, nasolabial furrowing and crying71.
These features disappear rapidly on completion of the examination. These pain
behaviours are frequently observed in babies undergoing screening even with
administration of local anaesthetic eye drops. No additional intervention,
113
pharmacological or non-pharmacological, is used routinely during eye examinations
on the Neonatal Unit. This is a common practice throughout the United Kingdom.
7.1.3 Analgesic effects of Sucrose and non-nutritive sucking
A variety of interventions, both pharmacological and non-pharmacological are
available for management of procedural pain in neonates. Sweet solutions have, for
many years, been noted to produce a calming effect in crying babies and infants
undergoing invasive procedures150. Sucking at the breast or on a pacifier has also
been shown to reduce pain responses151. Administration of sucrose with or without
non-nutritive sucking is the most widely studied non-pharmacological intervention
for pain relief in infants. The analgesic effects of sucrose and non-nutritive sucking
are thought to be mediated by both endogenous opioid and non-opioid receptors. A
recent Cochrane Review concluded that oral sucrose reduces procedural pain in
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neonates . It has been shown to decrease duration of crying and reduce behavioural
and physiological pain responses in babies undergoing heelstick or venepuncture153"
155. A wide range of doses has been investigated. Doses of less than 0.12g appear to
be ineffective and little increase in effect has been shown with doses greater than
0.5g156. No adverse effects have been reported with administration of single doses of
sucrose.
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7.1.4 Pain Relief in screening for retinopathy of prematurity
Infants undergoing screening examination have usually progressed from the initial
acute problems associated with prematurity and are often no longer receiving
intensive care. Therefore, they rarely have a requirement for regular analgesic
medication. Although local anaesthetic drops are administered prior to eye
examination, the majority of infants score highly on validated pain scores such as the
Premature Infant Pain Profile12 during the examination. Since eye examination
appears to be a painful procedure, there is a need to identify a safe and effective way
of providing procedural pain relief and of assessing the adequacy of analgesia. In this
group of more mature babies undergoing a brief, but acutely painful procedure, the
use of sucrose with or without a pacifier might be expected to attenuate the pain
response. This study was designed to study the effectiveness of sucrose as an
analgesic for this procedure and to investigate the effects of analgesia for acute pain
on mean heart rate and heart rate variability.
7.1.5 Study design and subjects
This was a randomised placebo-controlled study. 34 infants were included in the
study. All met the criteria for screening for retinopathy of prematurity on the basis of
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birth weight and/or gestational age. Babies receiving mechanical ventilation and
those receiving nothing by mouth were excluded from the study. Any infant
receiving concurrent alternative analgesic medication was also excluded. Babies
receiving continuous positive airways pressure via nasal prongs (nCPAP) who were
stable and comfortable on this form of airway support were not excluded.
Only the first eye examination for each baby was considered. This was to overcome
potential confounding effects that might occur if a baby were to anticipate a
procedure following previous exposure to the same painful stimulus. A single
ophthalmologist carried out all examinations. The Lothian Research Ethics
Committee granted ethical approval for the study and written consent was obtained
from the parents of all infants.
7.2 METHODS
7.2.1 Allocation of treatment
Infants were randomised to receive one of the following four interventions two
minutes prior to the start of one of the screening eye examinations. The start of the
examination was defined as the time of administration of local anaesthetic eye drops:
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1. 1ml sterile water given by mouth using a syringe.
2. 0.5ml Syrup BP (sucrose 66%) diluted with 0.5 ml sterile water
(to give a dose of sucrose 0.33g) given by mouth using a syringe.
3. 1ml sterile water given by mouth using a syringe and pacifier put
into the mouth.
4. 0.5ml Syrup BP (sucrose 66%) diluted with 0.5 ml sterile water
(to give a dose of sucrose 0.33g) given by mouth using a syringe
and pacifier put into the mouth.
Investigators, staff and parents were blind to the identity of the study medication, but
could not be blind to the use of the pacifier.
7.2.2 ECG monitoring
ECG recording using the Braemar DL700 holter monitor (see Chapter 5, Section
5.2.1.2) connected to the baby's chest by five gel electrodes was started prior to
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administration of local anaesthetic eye drops and continued for at least one minute
after completion of the procedure. Monitoring electrodes were applied several
minutes before monitoring was commenced, to allow the baby to return to a state of
rest before study measurements were recorded. During the examination, the times of
all events were noted: administration of study treatment, administration of local
anaesthetic eye drops, completion of examination as defined by removal of the lid
speculum following examination of the second eye.
7.2.3 Analysis of ECG data
Using the times recorded at the time of screening, periods before administration of
the study solution and then during and after the eye examination were identified.
These periods represent baseline, then deviation from the baseline during the painful
procedure, and lastly, recovery after the procedure. Ideally, it would have been most
appropriate, when examining the data, to identify the maximum deviation of heart
rate from baseline during the procedure. However, since each examination lasted
between two and nine minutes, the large amount of numerical data returned made
this impracticable. Instead, a random number generator [www.random.org] was used
to isolate a ten second block in the middle of the time spans before the study solution
was given and the baby was at rest. A 20 beat period was chosen from this block.
Similarly, a random block was chosen from the recovery period, between one and
two minutes after completion of the examination. For the period representing the eye
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examination itself 20 beat periods were analysed, at one-minute intervals. The
maximum value obtained for mean heart rate was chosen to represent the peak
deviation from baseline. The mean heart rate was calculated over the 20 beats and the
heart rate variability was calculated using the standard deviation about the mean.
7.3 RESULTS
34 infants were recruited to the study. Table 7 shows the characteristics of the babies
studied according to treatment allocation. Unfortunately, in spite of randomised
allocation of treatment, the characteristics of the four groups were not the same at the
time of entry to the study. There was a statistically significant difference between the
groups with respect to gestation at birth (p = 0.037) with the babies who received
placebo without pacifier, being of a lower gestational age than the other 3 groups.
However, the groups were not significantly different in birth weight or in the
corrected gestational age at the time of the eye examination. The lower gestational
age group, not surprisingly, also had a higher percentage of babies who required
intensive care and a higher percentage of them were given morphine during the first
days of life. The difference in the number of babies previously receiving morphine
reached statistical significance (p = 0.022). A number of the babies in each group
were receiving caffeine as a respiratory stimulant at the time of eye examination.
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Table 7.2 shows the behavioural states of the infants during the period immediately
before the ophthalmological examination was performed. At that point, the heart rate
leads had been positioned and time had been allowed for the babies to return to a
resting state after this intervention. No study drug had been given at this stage and it
therefore represents baseline measurements. Table 7.2 shows that some babies at this
time were still in active states, although most were in quiet or active sleep states.
Using Fisher's exact test, the difference in behavioural states between the groups is
significant at the 1% level (p =0.004). The group that later received both sucrose and
pacifier included the greatest proportion of babies in awake states.
Babies who were receiving respiratory support via nCPAP were only included in this
study if they were generally well otherwise and were considered to be comfortable
and stable. Four of the 34 babies were receiving nCPAP. Three of these were
randomised to placebo and one to sucrose. No infant on nCPAP was randomised to
suck on a pacifier.
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Table 7.1: Characteristics ofbabies studied




















































































0 p = 0.154
*Fisher's Exact Test
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Table 7.3 shows the baseline mean heart rates and heart rate variability for each of
the groups. There is a difference between both the mean heart rates and variability.
Both groups who later receive a pacifier have lower resting baseline heart rates than
the other groups. The group who receive placebo without pacifier have lower
baseline heart rate variability than the other three groups. Neither difference reaches
statistical significance.
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*One-way analysis of variance; Values are expressed as mean (SD)
7.3.1 Mean heart rate and heart rate variability during eye examination
Figures 7.1 and 7.2 show the results for heart rate and variability before the
examination (pre), during the examination (peak) and during recovery (post).
123
Figure 7.7
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Figure 7.2
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Table 7.4 shows the maximum deviation in mean heart rate from baseline during eye
examination. In each group, there is a rise in mean heart rate that is highly
statistically significant.




































*Paired samples T- test
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Table 7.5 shows the mean change in heart rate variability at the time of peak heart
rate during eye examination. There is a fall in variability with the increase in heart
rate in all intervention groups; on no occasion does this change reach statistical
significance. The group who received placebo alone shows an increase in heart rate
variability although this increase is not statistically significant.


































*Paired samples T- test
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Since there are significant differences between the groups at baseline, it is more
appropriate to analyse the groups according to change from baseline values for mean
heart rate and heart rate variability, rather than by absolute values.
Table 7.6 shows the maximum change in mean heart rate during the examination and
corresponding change in variability. The change is also shown as a percentage of the
baseline value for each group. Using analysis of variance, there is no statistically
significant difference between the four groups although there are trends in the
percentage change for both mean heart rate and variability. Mean heart rate increases
in all four groups during the examination. There is a decrease in variability in the
three intervention groups, but the group receiving placebo alone show an increase.
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Table 7.6: Change from baseline mean heart rate and heart rate variability
















































































*One-way analysis of variance; Values are expressed as mean (95% CI)
7.3.2 Mean Heart Rate and Heart Rate Variability during Recovery from
Eye Examination
Tables 7.7 and 7.8 show the difference between the baseline heart rate and that
during the recovery period, between one and two minutes following eye examination.
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The mean heart rate does not return to the pre-examination level in any of the study
groups. In all four groups, the mean heart rate remains significantly elevated
compared to baseline, but has decreased with respect to the maximum rate during
examination.




































*Paired samples T- test
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*Paired samples T- test
Table 7.9 and 7.10 show the mean differences in heart rate and heart rate variability
for the groups from the height of the examination to the recovery phase. In the
infants receiving sucrose without pacifier, the fall in heart rate from peak level to
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recovery is statistically significant. This is not the case in the other three groups.
Heart rate variability in three of the groups increases, though this is only statistically
significant in the infants receiving sucrose without pacifier. The change in variability
is not significant with any other intervention.



































*Paired samples T- test
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7.4 DISCUSSION
Randomisation in this study was carried out using a sealed envelope method.
However, differences in the baseline characteristics between the four groups are
clearly apparent. This makes it difficult to determine whether any differences in
response are due to the effect of the study treatment or to inherent differences in the
subjects studied. It would only be possible to eliminate such differences by recruiting
larger numbers of babies into the study. The study was designed primarily to explore
the efficacy of sucrose as an analgesic in eye examination. Power calculations were
performed to detect a difference in the behavioural response to examination, since
this is the most sensitive known indicator of acute pain. In view of the baseline
differences that have occurred by chance, this part of the study will be continued to
recruit additional babies. Although research has shown a change in heart rate
variability with acute painl6;l34, there are only few data exploring the effect of
analgesia on heart rate and heart rate variability17. It would, therefore be impossible
to determine the number of babies required to show a difference between the groups.
This work was carried out as an opportunistic study and must therefore be regarded
only as an exploration of the subject.
It is possible that some of the pre-study differences may have affected the results in a
number of ways. Altered behavioural and physiological responses to pain have been
demonstrated in infants who have undergone intensive care. Johnston and Stevens3
studied the effect of postnatal age on pain responses and showed that babies exposed
to intensive care had decreased behavioural responses to pain and higher heart rates
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when compared with newly born infants of similar gestation. This was also noted by
Grunau et al1"7 and may explain the higher baseline heart rates in the two groups with
lower gestational age at birth.
Little work has been done to investigate the effects of previous opiate analgesia on
physiological parameters later in life. Grunau et al demonstrated that infants treated
with morphine in the first weeks of life might have increased cardiac autonomic
responses to acute pain. 157 They suggest that these infants, as a result of previous
stress, may be in a state of ongoing stress. This concept is in keeping with the
hypothesis that a state of heightened arousal exists in these babies as a result of the
wind up phenomenon43.
In this study, there is a trend in the placebo only group towards a different reaction to
eye examination. In contrast to the other groups, heart rate variability, in this group
of infants, increases rather than decreases with the painful stimulus, though in none
of the groups does the change reach statistical significance. Characteristics of this
group that may play a part in this include the lower gestational age at birth, previous
morphine therapy and the lack of any active treatment intervention. Unfortunately, it
is not possible to clarify the relative contributions of each. The increase in variability
would not have been expected from previous work that has shown decreased heart
rate variability in infants with painful interventions such as heel stick16 and
venepuncture17.
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Behavioural state is known to influence both heart rate variability and pain
responses. In sleeping babies, variability is higher in active sleep states than quiet
sleep and is higher again in infants when awake. The period of rest after positioning
of the ECG leads was intended to allow the babies to settle into a state of quiet sleep.
However, the majority of babies were in active states before the intervention
suggesting that a longer interval would have been beneficial for standardisation of
methods. As well as having an effect on baseline values, the state differences might
also affect the change with the painful stimulus. Grunau and Craig demonstrated that
facial activity in response to pain differs with the behavioural state prior to the
7T
noxious stimulus . Awake infants show greater response than sleeping infants and
those in quiet sleep had smaller facial responses than those in active sleep. It is not
known whether there is a similar differential response in heart rate or heart rate
variability. Given the small numbers in this study, it would be unlikely to detect such
an effect.
With the onset of the eye examination, the pattern in mean heart rate is that which
would be expected. All groups show a significant tachycardia in response to pain and
there is no difference in the extent of this between the treatment groups. If the
analgesic intervention were effective, attenuation in the pain response might be
anticipated with the effective therapy. The fact that this is not evident implies that no
analgesic effect is seen. This may be because sucrose and/or pacifier are not useful as
analgesics, though research into pain responses on heelstick and venepuncture
indicate otherwise. An alternative explanation is that the pain caused by this
procedure is so severe that sucrose is not a potent enough analgesic to be appropriate
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in this situation. Increase in heart rate is seen with many different kinds of stress. It is
likely, given the highly significant change in the heart rate of the infants in all
groups, that mean heart rate is not a sensitive enough indicator of pain to be useful in
detecting a difference. The response in heart rate variability is interesting in that it
alters in the placebo group in the opposite direction from all groups of infants
receiving active intervention to alleviate pain suggesting a possible treatment effect
in the other groups. However, since the change is contrary to what would be
anticipated and the difference is not statistically significant, it is difficult to interpret
this information and it must be acknowledged that the difference in baseline
characteristics of this group may have influenced this response. The small numbers
in the groups also make spurious results possible. Additional information on the
behavioural responses of these infants may shed further light. Since behaviour is still
acknowledged as the most sensitive indicator of pain, differences not identified by
the study of heart rate and heart rate variability may become apparent.
Following completion of the examination, heart rate would be expected to fall as the
infant returns to a resting state. It is interesting to note that clinically, most infants
fell into a deep state of sleep immediately the examination was over and the eye
speculum was removed. However, this study shows that even one or two minutes
later, the heart rate is still significantly higher than baseline levels in all groups,
indicating that the infants are still in a state of stress. However, in the infants
receiving sucrose without pacifier, the fall in heart rate from peak level to recovery is
statistically significant. This is not the case in the other three groups. Heart rate
variability increases as stress diminishes. In the group given sucrose, the rise in
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variability from peak levels reaches statistical significance, while in the other three
groups there is no significant change following the procedure. The possibility exists,
therefore, that sucrose is effective and that this is seen as a more rapid and smooth
return to baseline levels once the painful experience has finished.
7.5 SUMMARY
Mean heart rate and heart rate variability were studied in 34 infants undergoing
screening examination for retinopathy of prematurity. The infants were randomly
allocated to four groups receiving sucrose or placebo with or without a pacifier.
There were significant differences between the different intervention groups at
baseline. There was no significant difference between the groups for heart rate
response during examination. Heart rate variability fell in three treatment groups, but
increased in the group who received placebo alone. This finding is in contrast to
previous work and is difficult to explain. Mean heart rate and heart rate variability in
infants receiving sucrose fell towards pre-examination levels more rapidly than in the
other groups. Investigation of behavioural responses may be more helpful in




This work set out to explore the relationships between acute/procedural and
subacute/chronic pain, heart rate variability and analgesia in premature infants in the
intensive care situation. The larger part of the work consisted of opportunistic studies
of infants in Edinburgh involved in a large multicentre study. The other part included
heart rate and heart rate variability monitoring as part of a small study to determine
the efficacy of sucrose as an analgesic. The small numbers of infants recruited to the
studies has limited the extent to which it has been possible to realise these aims. The
shortfall in actual numbers, compared with anticipated recruitment predictions is not,
however, due only to poor levels of recruitment of infants. Rather, there are a number
of contributing factors, most of which relate to change and advancement of clinical
practice.
The last 20 years has seen vast changes in the field of neonatology. Infants of lower
and lower gestational ages, which would previously not have been considered viable,
are now surviving158'159. Advances in intensive care methods and in particular
ventilation strategies have undoubtedly played a great part in this change. With
greater numbers of immature babies spending time receiving ventilatory support, and
successfully being discharged home following intensive care, research extended from
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exploration ofmeasures to improve survival, to include investigation of the effects of
interventions that have now become commonplace. The fact that infants on
ventilators almost certainly experience discomfort, pain or distress has been a source
of anxiety and a spur for researchers. Anand, a number of years ago, conceived the
idea for the N.E.O.P.A.I.N. Multicentre Trial. It was designed to address this concern
by investigating the use of morphine in preterm ventilated newborn infants and its
effect on neurological outcome. Feasibility for the definitive study was established
with the NOPAIN Trial, a pilot study, and the results of this were published in
1999160 £)uring the time at which the pilot study was in progress, infants of less than
29 weeks gestation in Edinburgh were routinely intubated at delivery and frequently
remained ventilated for a number of days or weeks. Recruitment of such infants in
the first hours of life was relatively unproblematic and Edinburgh's contribution to
the study, in terms of numbers, was substantial.
During the time since the pilot study and the definitive study, some aspects of both
obstetric and neonatal care have changed almost beyond recognition. These changes
have had significant implications not only for practice, but also for research in
extremely premature infants. Two such advances have been the more frequent use of
antenatal steroids in anticipated preterm delivery161 and the use of early surfactant
therapy162 which, in Edinburgh is now often administered in the delivery room and if
possible, before the first mechanical breath. Both of these have contributed to a
decline in the severity of lung disease in these high-risk neonates. Increasing
confidence in the use of nasal continuous positive airways pressure as alternative
respiratory support has meant that infants remain on ventilators for shorter periods of
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time and frequently for less than 24 hours163'164. In some cases, babies who may have
been ventilated for a significant length of time in the relatively recent past, now
escape ventilation completely165'166.
Whilst this sea change is remarkable and can only be applauded as a success story for
perinatal medicine, it has significant implications for the study of conditions and
treatments in the smaller group of infants now requiring full intensive care. The
number of infants available for recruitment to major studies such as the
N.E.O.P.A.I.N. Trial has been considerably reduced. The implications for smaller,
single centre research initiatives are even greater. This study has been adversely
affected by this phenomenon, with initial recruitment of babies being limited and
early withdrawal of infants from the study being common due to rapid improvement
that might not previously have been anticipated.
Another possible contributing factor to the low numbers of infants recruited for both
parts of this work is the number of parents declining participation on behalf of their
infants. In the United Kingdom, media coverage of recent high profile "scandals" has
done much to weaken confidence in the medical profession and may have led to
reduced willingness to enter into research trials167'168. However, this probably did not
make a significant difference in this case. The percentage of parents consenting to
involvement was high overall with recruitment of more than 70% for the Edinburgh
component of the N.E.O.P.A.I.N. study and around 90% for the study of sucrose
analgesia.
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The results and conclusions of the study must, therefore be interpreted with caution.
Studies including small numbers and incomplete data are well recognised both to
present difficulties in choice of statistical methods of analysis and to increase greatly
the chance of error when testing the significance of findings. Type I errors occur
when too low a level of significance is accepted to make an assertion that a
difference between populations exists. Throughout this work and according to
convention a p-value of 5% is accepted as statistically significant. Type II errors
occur when the sample size is too small to detect a difference that may in fact be
present and it is likely that this may have exerted an effect on the results. Power
calculations were not performed for any of the outcomes discussed in these studies.
Indeed, this would have been impossible given the nature of the work. This
unfortunately means that no conclusions can be drawn from any of the study results.
There are, however, some findings that reach or show a trend towards statistical
significance and these may warrant further investigation.
Decrease in heart rate and heart rate variability with morphine therapy indicates that
both may be useful measures of relief of pain or stress. Little is known about the
development of tolerance in the preterm neonate, but the disappearance of effects
seen with morphine suggests that this may be a factor. The study sought to identify
possible indicators of opiate withdrawal. The rebound tachycardia and increase in
heart rate variability seen in the morphine treated babies is worthy of further
research. It is possible that behavioural factors may provide additional evidence if
they are also considered in any further studies. There are interesting differences in
the responses of the infants according to gestational age. Numbers in the study
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prevent clarification of this, but one can speculate that this may reflect a dose effect,
since the doses in the groups were different depending on gestational age. This
possibility could be ruled out if morphine levels for all infants were available.
Further exploration of the effects ofmorphine should include this, or standardise the
dosing regimen across the gestational ages to avoid confounding.
The study of the cutaneous flexor withdrawal reflex, disappointingly, failed to
identify any significant differences in threshold between the groups other than during
the period of weaning. In further investigation of the phenomenon of opiate
withdrawal, this may prove a useful tool. However, modern electronic devices would
be more accurate than the nylon hairs used in this research.
The final study, looking at the effects of sucrose analgesia suffered from the
difficulties of small numbers and consequent on this, significant differences between
the groups at entry to the study. No significant effects were found on the basis of this
work, and in spite of the recognised difficulties in this particular study, it is likely
that heart rate and heart rate variability are not the most effective way of assessing
the response to an intense stimulus such as eye examination. It is likely that the
effects of eye examination on cardiovascular parameters are significantly influenced
by factors other than pain. For, example, it is known that indentation of the eye,
which may, but does not necessarily occur during such an examination can have a
profound vagal effect and induce bradycardia. It is impossible to know how much
this may have affected the results of this investigation. Further investigation of the
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effects of pain relief in eye examination should probably be directed towards
behavioural responses.
Although there are significant limitations associated with this work, it is the only
work to date specifically investigating the effects of analgesia on heart rate and heart
rate variability in preterm neonates. As such, it contributes to the body of knowledge
in the study of pain in the newborn. A number of hypotheses have been generated
which suggest that further research is warranted, particularly on the subjects of opiate
withdrawal and appropriate morphine dosing according to gestational age. The extent
to which future research concerning morphine therapy may be carried out will
depend to a certain extent on the results of the N.E.O.P.A.I.N. trial yet to be
published. If morphine therapy is shown either to afford unquestionable benefit or
harm in this population, then it is unlikely that such research will continue to be
regarded as ethical. The importance of taking any opportunities as they rise to
conduct even small studies to learn about conditions and treatment is evident, whilst
recognising the obvious limitations of this approach. However, any future research in
this field should, if possible, be in the form of large randomised controlled trials to
avoid the problems associated with small study sample sizes.
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